Document:

EX-4.19

 Exhibit 4.19 

Portions of this Exhibit have been redacted because they are both (i) not material and (ii) are the type that the registrant treats as
private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. 

SUBSCRIPTION AGREEMENT 

THIS SUBSCRIPTION AGREEMENT (this “Agreement”)
is made and entered into as of July 19, 2022 (the “Effective Date”), by and between LUMIRADX LIMITED (registered number 314391), a public limited company incorporated in the Cayman Islands whose
registered office is c/o Ocorian Trust (Cayman) Limited, PO Box 1350, Windward 3, Regatta Office Park, Grand Cayman KY1-1108 Cayman Islands (the “Company”), and
the BILL & MELINDA GATES FOUNDATION, a Washington charitable trust that is a
tax-exempt private foundation organized and existing under the laws of Washington and having its principal place of business at 500 Fifth Avenue North, Seattle, Washington 98109, United States
(“Subscriber”). 
 BACKGROUND 

(A) WHEREAS, Subscriber and the Company are parties to an Amended and Restated Letter Agreement, dated October 17,
2019 (the “Cooperation Agreement”), pursuant to which the Company has agreed to certain global access commitments, including, inter alia: (i) in relation to the development by the Company of an HIV viral load assay and
the development of a manufacturing, commercialization and distribution strategy for point-of-care diagnostics within low and middle income countries, including the HIV
viral load assay; (ii) to provide an option for Subscriber to continue to provide funding to advance the HIV viral load assay through commercialization and launch; (iii) to provide an option for Subscriber to fund up to five additional
assay products; (iv) to provide an option for Subscriber to fund a project to accelerate commercialization of the Company’s products in certain specified low and middle income countries; (v) to conduct certain activities in respect of
partnering with health systems for low income people in challenging markets; and (vi) to develop the next-generation “V7” diagnostic instrument that is low-cost, robust and appropriate for all
clinical settings. 
 (B) WHEREAS, in furtherance of its charitable mission, Subscriber desires to provide
additional funding to the Company to be used by the Company solely for the purpose of providing continued support for the commercialization of the Company’s products in certain specified low- and
middle-income countries, additional support for the Company’s tuberculosis program and additional support for further assay and/or instrument development.

(C) Accordingly, the Company and Subscriber desire to enter into this Agreement, pursuant to which Subscriber agrees to subscribe for US$25,000,000 of
the Company’s common shares, par value $0.0000028 per common share (“Common Shares”), in a private placement and the Company and the Subscriber agree to enter into a further amendment and restatement of the Cooperation
Agreement (the “Amended and Restated Agreement”) (the agreed form of which is set out in the Schedule to this Agreement). 

AGREEMENT 

NOW, THEREFORE, in consideration of the foregoing recitals and the mutual promises,
warranties, and covenants hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 

1.    SUBSCRIPTION. Subject to the terms and conditions hereof, Subscriber
shall, in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), subscribe for that number of Common Shares, rounded down to avoid fractional Common
Shares being issued (the “Securities”), determined by dividing US$25,000,000 (the “Subscription Amount”), by the price per Common Share at which the Common Shares are offered to the public in the
Company’s proposed registered offering of Common Shares (the “Offering”) pursuant to the Form F-1 Registration Statement to be filed by the Company with the Securities and Exchange
Commission (the “Commission”) in connection therewith (the “Registration Statement”), as amended, as set forth on the cover page of the final prospectus for the Offering (the “Offering
Price”). 
 2.    AGREEMENT TO SUBSCRIBE. 

2.1    Subscription for Securities. Subject to the terms and conditions hereof, Subscriber hereby applies for
and agrees to subscribe for, and the Company accepts such application and will allot and issue to the Subscriber, in a private placement exempt from the registration requirements of the Securities Act, the Securities at a subscription price per
Common Share equal to the Offering Price. 

 2.2    Closing Date. The subscription for the Securities
(the “Closing”) shall take place, subject to the satisfaction or waiver of the Conditions (other than those Conditions that are to be satisfied on the Closing) on the first business day following the satisfaction of the
Conditions (or at such other date as agreed between the Company and the Subscriber) remotely via the exchange of documents (the date of such Closing is hereinafter referred to as the “Closing Date”). 

2.3    Actions by Subscriber and the Company at Closing. At the Closing, (i) the Subscriber shall pay
the Subscription Amount by wire transfer of immediately available funds to an account specified in writing by the Company and, subject to receipt thereof, the Company will procure the allotment of and will issue and deliver, or cause to be
delivered, the Securities to the Subscriber in book-entry form and provide evidence of the same to the Subscriber, no later than five business days after the Closing Date; and (ii) the Company and the Subscriber shall enter into the Amended and
Restated Agreement and deliver to each other a duly executed counterpart of such Amended and Restated Agreement. 

3.    WARRANTIES OF THE COMPANY. 

Except as may be disclosed separately by the Company to the Subscriber on or prior to the date hereof, the Company hereby warrants to
Subscriber as follows as of the date hereof and as of the Closing Date (except for the warranties that speak as of a specific date, which shall be made as of such date): 

3.1    Organization; Qualification. The Company is a company duly incorporated, validly existing and in good
standing under the laws of the Cayman Islands and has all requisite corporate power and authority to carry on its business as now conducted. The Company has at all times complied with all provisions of its articles of association (the
“Articles”) and is not in default under, or in violation of, any provision of the Articles. The Company is not, and has never been, a “shell company,” as described in paragraphs (i)(1)(i) and (ii) of Rule
144 promulgated under the Securities Act. 
 3.2    Capitalization. The issued and outstanding share
capital of the Company as of March 31, 2022 was comprised of 68,341,044 Common Shares and 185,343,353 A ordinary shares, par value $0.0000028 per ordinary share (“Ordinary Shares”), and, as of such date, there were no
securities convertible, exercisable or exchangeable into shares in the Company other than: (i) 11,163,930 Common Shares issuable upon the exercise of outstanding stock options; (ii) 80,667,058 Ordinary Shares issuable upon the exercise of
outstanding stock options; (iii) 13,578,241 Common Shares issuable upon the exercise of outstanding warrants; (iv) 5,403,892 Ordinary Shares issuable upon the exercise of outstanding warrants; and (v) 6,126,554 Common Shares reserved for issuance
upon conversion of the 6.0% Convertible Senior Subordinated Notes due 2027 (the “Convertible Notes”) assuming the initial conversion rate of 108.4346 Common Shares per $1,000 principal amount of Convertible Notes, as provided for in the
indenture governing the Convertible Notes. All of the issued and outstanding shares of the Company’s capital stock have been duly authorized and are validly issued, fully paid and nonassessable. None of such shares were issued in violation of
any preemptive rights or other similar rights of third parties and such shares were issued in compliance with applicable state and federal securities laws. 

3.3    Authorization; Binding Obligations. The Company has all requisite power and authority to execute and
deliver this Agreement and any and all instruments necessary or appropriate in order to effectuate fully the terms and conditions contained herein and all related transactions and to perform its obligations hereunder. This Agreement and the
allotment, issuance, and delivery of the Securities have been duly authorized by any necessary action on the part of the Company, and this Agreement has been duly executed by the Company and constitutes the valid and legally binding obligation of
the Company enforceable in accordance with its terms and conditions. The authorization, allotment, issuance, and delivery of the Securities have been duly authorized by any requisite action of the Company’s board of directors (the
“Board”) and shareholders. 
 3.4    Valid Issuance of the Securities; Exemption from
Registration. When issued in accordance with this Agreement, the Securities will be (i) duly and validly issued, fully paid, free of any liens, options, encumbrances, proxies, adverse claims or restrictions imposed by the Company except as
set forth in applicable law or the Articles and (ii) assuming the accuracy of the Subscriber’s warranties in this Agreement at the time of such issuance, exempt from registration and/or qualification under the Securities Act and all
applicable U.S. state securities laws, and issued in compliance with all applicable securities laws. 

  
 2 

3.5    Non-Contravention. No consent, approval, notice, order or
authorization of, or registration, qualification, designation, declaration or filing with, any U.S. or Cayman Islands governmental authority (other than filings required to be made in accordance with the Companies Act (as revised) of the Cayman
Islands, pursuant to applicable state or federal securities laws, or the rules and regulations of The NASDAQ Stock Market) on the part of the Company is required in connection with (i) the authorization and execution of this Agreement or
(ii) the authorization, allotment and issuance of the Securities pursuant to this Agreement. The Company is not in violation or default of any instrument, judgment, order, writ, decree or contract to which the Company is a party or by which the
Company is bound or of any provision of any statute, rule or regulation applicable to the Company, which violation or default would materially and adversely affect the business of the Company. 

3.6    Compliance with Securities Laws; No Integration. Assuming the accuracy of the Subscriber’s
warranties, the allotment and issuance of the Securities will not be in violation of the Securities Act, the Securities Exchange Act of 1934, as amended (the “Exchange Act”), any US state securities laws, or the Articles,
when allotted and issued in accordance with this Agreement. Neither the Company nor its subsidiaries or any controlled affiliates, nor any person acting on its or their behalf, has, directly or indirectly, made any offers or sales of any Common
Shares under circumstances that would adversely affect reliance by the Company on Section 4(a)(2) and Regulation D of the Securities Act for the exemption from registration of Securities issued pursuant to a private placement, as contemplated
by this Agreement, or would otherwise require registration of the Securities under the Securities Act as an integrated offering. 

3.7    Investment Company. The Company is not and, immediately after giving effect to the offering,
allotment and issue of the Securities, will not be an “investment company” as defined in the Investment Company Act of 1940, as amended. 

3.8    No General Solicitation. Neither the Company nor its subsidiaries or any controlled affiliates, nor
any person acting on its or their behalf, has offered or sold any of the Securities by any form of general solicitation or general advertising. 

3.9    F-1 Registration Statement. The Registration Statement, when
filed, will conform, and the final prospectus forming a part of the Registration Statement (the “Prospectus”) and any further amendments or supplements to the Registration Statement or the Prospectus, will conform, in all
material respects, to the requirements of the Securities Act and the rules and regulations of the Commission thereunder and will not, as of the applicable effective date as to the Registration Statement and any amendment thereto, and as of its date
as to the Prospectus and any amendment or supplement thereto, contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. 

3.10    “Bad Actor” Status. Neither the Company nor any of its Rule 506(d) Related Parties (as
defined below) is a “bad actor” within the meaning of Rule 506(d) promulgated under the Securities Act. For purposes of this Agreement, “Rule 506(d) Related Party” shall mean a person or entity covered by the
“Bad Actor disqualification” provision of Rule 506(d) of the Securities Act. 

4.    WARRANTIES OF SUBSCRIBER. 

4.1    Investment Warranties. 

(a)    The Subscriber warrants to the Company that: (i) it is an “accredited investor” as defined in
Rule 501(a) of Regulation D of the Securities Act; (ii) it has sufficient knowledge and experience in investing in companies similar to the Company in terms of the Company’s stage of development, so as to be able to evaluate the risks and
merits of its investment in the Company and it is able financially to bear the risks thereof; (iii) it has had an opportunity to discuss the Company’s business, management and financial affairs with the Company’s management; and
(iv) its financial condition is such that it is able to bear the risk of holding the Securities for an indefinite period of time and can bear the loss of the entire investment in such securities. 

(b)    This Agreement is made in reliance upon the Subscriber’s express representations that (i) the
Securities being subscribed for by such Subscriber are being acquired for such Subscriber’s own account (and not on behalf of any other person or entity) and not with a view to, or for sale in connection with, the distribution thereof, nor with
any present intention of distributing or selling the Securities or any portion thereof, (ii) the Subscriber was not organized for the specific purpose of acquiring the Securities and (iii) the Securities will not be sold by the Subscriber
without registration under the Securities Act and applicable state securities laws, or an exemption therefrom. The Subscriber is not a broker-dealer registered with the Commission under the Exchange Act or an entity engaged in a business that would
require it to be so registered. 

  
 3 

 (c)    Subject to Section 6.3, the Subscriber
understands that until such time as the Securities shall have been registered under the Securities Act and applicable state securities laws or shall have been transferred in accordance with an opinion of counsel reasonably satisfactory to the
Company that such registration is not required, stop transfer instructions will be issued to the Company’s transfer agent, and any certificate or certificates and any book-entry representing such Securities shall bear a restrictive legend
stating that such Securities have not been registered under the Securities Act and applicable state securities laws and referring to restrictions on the transferability and sale thereof. The Subscriber further understands that its warranties
hereunder will not preclude disposition of the Securities without registration thereof, in compliance with Rule 144 promulgated under the Securities Act (“Rule 144”). 

4.2    Receipt of Information. The Subscriber believes it has received all the information the Subscriber
considers necessary or appropriate for deciding whether to purchase the Securities. Subscriber has been afforded an opportunity to ask questions of and receive answers from representatives of the Company concerning the terms and conditions of this
Agreement, the subscription for the Securities, the Company’s business, operations, market potential, capitalization, financial condition and prospects, and all other matters deemed relevant by the Subscriber. The foregoing, however, does
not limit or modify the warranties of the Company in Section 3 of this Agreement. 

4.3    Authorization. The Subscriber has all requisite power and authority to execute and deliver this
Agreement. This Agreement constitutes the valid and legally binding obligation of the Subscriber, enforceable against the Subscriber in accordance with its terms. 

4.4    “Bad Actor” Status. Subscriber hereby warrants that neither it nor any of its Rule 506(d)
Related Parties is a “bad actor” within the meaning of Rule 506(d) promulgated under the Securities Act. 

4.5    Legends. Subscriber understands that the Securities will be characterized as “restricted
securities” under the US federal securities laws and agrees that the certificates or book-entry confirmations evidencing or confirming the Securities, or any other securities issued in respect of the Securities upon any share split, share
consolidation, recapitalization, or similar event, shall bear the restrictive legend in substantially the following form, subject to Section 6.3. 

“THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND HAVE BEEN ACQUIRED FOR
INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH TRANSFER MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, RELATED THERETO AND COMPLIANCE
WITH APPLICABLE STATE SECURITIES LAWS, A VALID EXEMPTION FROM SUCH REGISTRATION REQUIREMENTS OR AN OPINION OF COUNSEL IN A FORM REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED, OR APPLICABLE STATE SECURITIES LAWS.” 
 5.    CONDITIONS TO
CLOSING (THE “CONDITIONS”). 
 5.1    Conditions to
Subscriber’s Obligations at the Closing. The obligations of Subscriber under this Agreement are subject to the satisfaction (or, if permitted by law, waiver in writing by the Subscriber), at or prior to the Closing Date, of the following
conditions: 
 (a)    Qualifying Financing. Following the date of this Agreement and at or prior to the
Closing, the Company shall have received gross proceeds in an aggregate amount equal to or greater than US$75,000,000 (or its equivalent in another currency or currencies) through the sale of Common Shares, excluding the proceeds to be received
pursuant to this Agreement and the Company shall have provided evidence of the receipt of such amount of gross proceeds that is acceptable to the Subscriber. 

(b)    No Injunction, etc. No preliminary or permanent injunction or other binding order,
decree or ruling issued by a court or governmental agency shall be in effect which shall have the effect of preventing the consummation of the transactions contemplated by this Agreement. No action or claim shall be

  
 4 

 
pending before any court or quasi-judicial or administrative agency of any federal, state, local or foreign jurisdiction or before any arbitrator wherein an unfavorable injunction, judgment,
order, decree, ruling or charge would be reasonably likely to (i) prevent consummation of any of the transactions contemplated by this Agreement, (ii) cause any of the transactions contemplated by this Agreement to be rescinded following
consummation or (iii) have the effect of making illegal the purchase of, or payment for, any of the Securities by the Subscriber. 

(c)    Warranties True. The warranties in Section 3 made by the Company shall be true
and correct in all material respects (except for such warranties that are qualified by materiality, which shall be true and correct in all respects) on and as of the Closing Date with the same effect as though such warranties had been made on and as
of such date, except to the extent expressly made as of a specified date, which shall be true and correct as of such date. 

(d)    Performance. The Company shall have performed and complied with all covenants, agreements,
obligations and conditions contained in this Agreement that are required to be performed or complied with by it on or before the Closing Date. 

(e)    Securities Law Compliance. The offer and sale of the Securities to the Subscriber pursuant to
this Agreement shall be exempt from the registration requirements of the Securities Act and the registration and/or qualification requirements of all applicable state securities laws. 

(f)    Consents, Permits, and Waivers. All consents, permits and waivers, if any, of any governmental
authority or regulatory body that are required in connection with the transactions contemplated by this Agreement shall have been duly obtained and shall be effective on and as of the Closing. 

(g)    Documents. The Company shall deliver or procure the delivery to the Subscriber of the Amended
and Restated Agreement, duly executed by the Company. 
 5.2    CONDITIONS TO
OBLIGATIONS OF THE COMPANY. The obligations of the Company under this Agreement are subject to the satisfaction (or, if permitted by law, waiver in writing by the
Company), on or prior to the Closing Date, of the following conditions: 
 (a)    Warranties True. The
warranties in Section 4 made by Subscriber shall be true and correct in all material respects (except for such warranties that are qualified by materiality which shall be true and correct in all respects) on and as of the Closing
with the same effect as though such warranties had been made on and as of the Closing. 

(b)    Performance. The Subscriber shall have performed and complied with all covenants, agreements,
obligations and conditions contained in this Agreement that are required to be performed or complied with by it on or before the Closing Date. 

(c)    Securities Law Compliance. The offer and sale of the Securities to the Subscriber pursuant to
this Agreement shall be exempt from the registration requirements of the Securities Act and the registration and/or qualification requirements of all applicable state securities laws. 

(d)    Consents, Permits, and Waivers. All consents, permits and waivers, if any, of any governmental
authority or regulatory body that are required in connection with the transactions contemplated by this Agreement shall have been duly obtained and shall be effective on and as of the Closing. 

(e)    Documents. The Subscriber shall deliver or procure the delivery to the Company of the Amended
and Restated Agreement, duly executed by the Subscriber. 
 6.    REGISTRATION RIGHTS;
RULE 144; LEGEND REMOVAL. 
 6.1    Registration
Rights. The Securities shall be “Registrable Securities” as that term is defined in the Amended and Restated Registration Rights Agreement, dated September 28, 2021, by and among the Company, CA Healthcare Acquisition Corp.,
a Delaware corporation, CA Healthcare Sponsor LLC, a Delaware limited liability company, and the equityholders of the Company listed on Exhibit A attached thereto (the “Registration Rights Agreement”), and the Subscriber will
be entitled to the registration rights set forth in the Registration Rights Agreement for so long as such Securities remain Registrable Securities. 

  
 5 

 6.2    Rule 144 Reporting. With a view to making
available to the Subscriber the benefits of certain rules and regulations of the Commission which may permit the sale of the Securities to the public without registration, the Company agrees to use commercially reasonable efforts to: 

(a)    make and keep public information available, as those terms are understood and defined in Rule 144; 

(b)    file with the Commission in a timely manner all reports and other documents required of the Company under
the Exchange Act; and 
 (c)    furnish the Subscriber forthwith upon request (i) a written statement by
the Company as to its compliance with the public information requirements of Rule 144, (ii) a copy of the most recent periodic report of the Company, and (iii) such other reports and documents as may be reasonably requested in availing the
Subscriber of any rule or regulation of the Commission permitting the sale of any such securities without registration. 

6.3    Removal of Restrictive Legend. The Securities, when issued, shall not bear the restrictive
legend set forth in Section 4.5: (i) following a sale of such Securities pursuant to a registration statement covering the resale of such Securities, while such registration statement is effective under the Securities Act, (ii) following
any sale of such Securities pursuant to Rule 144, (iii) if such Securities are eligible for sale under Rule 144, without the requirement for the Company to be in compliance with the current public information required under Rule 144 as to such
Securities and without volume or manner-of-sale restrictions or (iv) if such legend is not required under applicable requirements of the Securities Act (including
judicial interpretations and pronouncements issued by the staff of the Commission). The Company agrees that at such time as the restrictive legend set forth in Section 4.5 is no longer required under this section, then no later than
five (5) business days following delivery by the Subscriber to the Company of customary representations regarding the facts to support the removal of the restrictive legends, the Company shall (x) in the event that such Securities are
certificated, deliver or cause to be delivered to the Subscriber a certificate representing such Securities that is free from such restrictive legend, or (y) cause the removal any such restrictive legend in the Company’s records of its
share capital. 
 7.    MISCELLANEOUS. 

7.1    Withdrawal Right. The Securities to be issued pursuant to this Agreement shall be subject to the
Withdrawal Right (such term as is defined in the Cooperation Agreement), and nothing in this Agreement is intended to limit, diminish or contradict the rights and obligations of the parties in the Cooperation Agreement. In the event of any
inconsistency between this Agreement and the Cooperation Agreement, the Cooperation Agreement shall control. 

7.2    Costs and Expenses. Each Party shall bear its own costs and expenses in connection with negotiation
of this Agreement. 
 7.3    Governing Law. This Agreement (and any dispute or claim relating to it or its
subject matter (including non-contractual claims)) is governed by and is to be construed in accordance with English law. 

7.4    Jurisdiction. The parties irrevocably agree that the courts of England and Wales shall have exclusive
jurisdiction to settle any claim, dispute or issue (including non-contractual claims) which may arise out of or in connection with this Agreement or its enforceability. 

7.5    Survival. The warranties of the Company and Subscriber contained in or made pursuant to this
Agreement shall survive, any investigation made by the Subscriber, the execution and delivery of this Agreement and the Closing. 

  
 6 

 7.6    Successors and Assigns. The terms and conditions of
this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their
respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. Neither the Company nor Subscriber shall have the right to assign this
Agreement without the prior written consent of the other party. 
 7.7    Entire Agreement. This Agreement
including the exhibits and schedules attached hereto, constitutes the full and entire understanding and agreement between the parties with regard to the subjects hereof and thereof and no party shall be liable for or bound to any other in any manner
by any oral or written representations, warranties, covenants and agreements except as specifically set forth herein and therein. 

7.8    Severability. In the event one or more of the provisions of this Agreement should, for any reason, be
held by a court of competent jurisdiction to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Agreement, and this Agreement shall be construed as if
such invalid, illegal or unenforceable provision had never been contained herein. Upon such determination that any term or other provision is invalid, illegal or unenforceable, the parties hereto shall negotiate in good faith to modify this
Agreement so as to effect the original intent of the parties as closely as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the greatest extent possible. 

7.9    Amendment and Waiver. This Agreement may be amended or modified, and the rights and the obligations
of the Company and the rights and obligations of Subscriber may be waived, only upon the written consent of the Company and Subscriber. 

7.10    Notices. All notices and other communications which are required or permitted hereunder will be in
writing and sufficient if delivered personally, sent by electronic mail or facsimile (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by nationally-recognized overnight courier or sent by
registered or certified mail, postage prepaid, return receipt requested, addressed as follows: 
  

			
	To the Company:	  	 LumiraDx Limited
 c/o Ocorian Trust (Cayman)
Limited, PO Box 1350, Windward 3, Regatta Office Park, Grand Cayman KY1-1108 Cayman Islands92 Attention: Veronique Ameye, General Counsel and Company Secretary

Email: veronique.ameye@lumiradx.com

	
	With a copy, which shall not constitute notice, to:
		
		  	 Fried, Frank, Harris, Shriver & Jacobson (London) LLP

100 Bishopsgate, London EC2N 4AG Attention: Ian Lopez
 Email:
ian.lopez@friedfrank.com

		
	To Subscriber:	  	 Bill & Melinda Gates Foundation
 PO Box
23350
 Seattle, Washington 98102
 United States

Attention: Vidya Vasu-Devan, Director, Strategic Investment Fund

Email: SIFPortfolio@gatesfoundation.org

	
	With a copy, which shall not constitute notice, to:
		
		  	 Morgan, Lewis & Bockius LLP
 Attention:
Celia Roady
 Email: celia.roady@morganlewis.com

 or to such other address as the party to whom notice is to be given may have furnished to the other party in writing in
accordance herewith. Any such notice will be deemed to have been given: (a) when delivered if personally delivered on a business day (or if delivered or sent on a non-business day, then on the next
business day); (b) on the business day of receipt if sent by overnight courier or electronic mail; or (c) on the business day of receipt if sent by mail. 

  
 7 

 7.11    Titles and Subtitles. The titles of the sections and
subsections of this Agreement are for convenience of reference only and are not to be considered in construing this Agreement. 

7.12    Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be
an original, but all of which together shall constitute one instrument. Any or all parties may execute this Agreement by facsimile signature or scanned signature in PDF format and any such facsimile signature or scanned signature, if identified,
legible and complete, shall be deemed an original signature and each of the parties is hereby authorized to rely thereon. 

7.13    Broker’s Fees. Each party hereto warrants that no agent, broker, investment banker, person or
firm acting on behalf of or under the authority of such party hereto is or will be entitled to any broker’s or finder’s fee or any other commission directly or indirectly in connection with the transactions contemplated herein. Each party
hereto further agrees to indemnify each other party for any claims, losses or expenses incurred by such other party as a result of the warranties in this Section 7.13 being untrue. 

7.14    Termination. The parties hereto may terminate this Agreement by mutual written agreement. In
addition, this Agreement may be terminated by either Subscriber or the Company on written notice to the other party if Closing has not occurred before August 31, 2022. 

[THE REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK] 

  
 8 

 IN WITNESS WHEREOF, the
parties hereto have executed this Agreement as of the date first set forth above. 
  

									
	EXECUTED by LUMIRADX LIMITED	 	                        	 	)	 	 /s/ R. Zwanziger

	acting by a duly authorized officer	 		 	)	 	Name:	 	Ron Zwanziger
		 		 		 	Title:	 	Chief Executive Officer
				
	EXECUTED by the BILL & MELINDA GATES	 		 	)	 	 /s/ Carolyn Ainslie

	FOUNDATION acting by a duly authorized officer	 		 	)	 	Name:	 	Carolyn Ainslie
		 		 		 	Title:	 	Chief Financial Officer

  
 9 

 SCHEDULE 

Amended and Restated Agreement 

 July     , 2022 

LumiraDx Limited 
 3 More London Riverside 

London 
 SE1 2AQ 

United Kingdom 
 Attention: Chief Executive Officer, Chairman and
Director 
 Re: Strategic Relationship between the Bill & Melinda Gates Foundation and LumiraDx Limited 

Ladies and Gentlemen: 
 This Second Amended and
Restated Letter Agreement (including all appendices and attachments hereto, the “Letter Agreement”) is entered into as of July     , 2022 between the Bill & Melinda Gates Foundation (the
“Foundation”), a Washington charitable trust that is a tax exempt private foundation, and LumiraDx Limited, an exempted company with limited liability incorporated in the Cayman Islands under company number 314391 with its
registered office at c/o Ocorian Trust (Cayman) Limited, PO Box 1350, Windward 3, Regatta Office Park, Grand Cayman KY1 1108, Cayman Islands (the “Company”). This Letter Agreement amends and restates in its entirety the Amended and
Restated Letter Agreement entered into by and between the Company and the Foundation effective as of October 17, 2019 (the “Revised Agreement”) in connection with the Foundation’s program-related investment in the form of
a loan by the Foundation to the Company in the amount of US$18,000,000 (the “Note Investment”); which amended and restated in its entirety the Letter Agreement entered into by and between the Company and the Foundation effective as
of July 17, 2018 (the “Original Agreement”) in connection with the Foundation’s program related investment in the amount of US$19,998,823 in the Series A Convertible Preferred Shares of the Company (the “Preferred
Investment”). This Letter Agreement is being entered into in connection with the program-related investment in the amount of US$25,000,000 in the Common Shares or Perpetual Preferred Shares of the Company (the “Equity
Investment”, and together with the Note Investment and the Preferred Investment the “Foundation Investment”). The Foundation Investment is subject to the terms and conditions of the Subscription Agreement entered into by
and between the Company and the Foundation effective as of July     , 2022, any other documents executed in connection with the Equity Investment, and the documents executed in connection with the Note Investment and the
Preferred Investment (collectively, and together with this Letter Agreement and any additional documents that may be executed in connection with the Foundation Investment, in each case as amended from time to time in accordance with their terms, the
“Investment Documents”). The Foundation is making the Foundation Investment to induce the Company to perform the Global Access Commitments set forth herein, and the Company acknowledges and agrees that it would not undertake such
Global Access Commitments absent the Foundation Investment. The Foundation Investment is being made in accordance with the provisions of the Investment Documents and is conditioned upon the execution and delivery of the applicable Investment
Documents by the parties thereto and the Foundation obtaining written legal opinions from tax counsel that the Foundation Investment qualifies as a program-related investment under the Code. 

 In consideration of the Foundation making the Foundation Investment on the terms and conditions stated
herein and in the other Investment Documents, and for other good and valuable consideration, the parties hereto hereby irrevocably agree as follows: 
  

	1.	 Definitions. 

For the purposes of this Letter Agreement the following terms have the meanings indicated. 

“Accelerated Commercialization Commitment” has the meaning given in Section 3(g)(i). 

“Archetype Health System” has the meaning given in Section 3(g)(ii). 

“Additional Assay Project” has the meaning given in Section 3(f)(i). 

“Additional Project” has the meaning given in Section 3(f)(i). 

“Affiliate” means, as to any person or entity, any person or entity that, directly or indirectly, controls, is controlled by or is under
common control with such person or entity at any time and for so long as that control exists, where “control” (for purposes of this definition of “Affiliate” only) means having the decision-making authority as to the person or
entity and, further, where that control will be deemed to exist where a person or entity owns more than 50% of the equity (or that lesser percentage that is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction)
entitled to vote regarding composition of the board of directors or other body entitled to direct the affairs of the person or entity. 

“Acquisition Transaction” means (a) the acquisition, directly or indirectly, after the date of this Letter Agreement, by any person or
group (within the meaning of Section 13(d)(3) of the Exchange Act) of beneficial ownership of securities of the Company possessing more than 50% of the total combined voting power of all outstanding voting securities of the Company, (b) a
merger, consolidation or other similar transaction involving the Company, except for a transaction in which the holders of the outstanding voting securities of the Company immediately prior to such merger, consolidation or other transaction hold, in
the aggregate, securities possessing more than 50% of the total combined voting power of all outstanding voting securities of the surviving entity immediately after such merger, consolidation or other transaction, or (c) an assignment, sale,
transfer or exclusive license of all or substantially all of the Company’s assets, whether by merger, stock transfer, or otherwise. 

“Challenging Market Countries” means those countries described as “Challenging Market Countries” on Appendix A. 

“Charitability Default” has the meaning given in Section 5(b). 

“Charitable Purpose” has the meaning given in Section 2(a). 

“Claim” has the meaning given in Section 14. 

“Code” means the U.S. Internal Revenue Code of 1986, as amended. 

 “Commitment to Gender Diversity” has the meaning given in Section 7. 

“Company” has the meaning given in the introductory paragraph. 

“Developing Countries” means those countries described as “Developing Countries” on Appendix A. 

“Equity Investment” has the meaning given in the introductory paragraph. 

“Exchange Act” means the Securities Exchange Act of 1934, as amended. 

“Fair Market Value” means (a) if the Foundation Securities are freely tradable, the closing price of the Foundation Securities on the
most recent day the Foundation Securities were traded on the applicable exchange prior to the closing date of the redemption or purchase or (b) if the Foundation Securities are not freely tradable, the then current fair market value as
determined by a mutually agreed upon (such agreement not to be unreasonably withheld) independent third-party appraiser. 
 “Fast Labs
Products” has the meaning given in Section 3(c). 
 “Fast Labs Project” has the meaning given in Section 3(c). 

“Foundation” has the meaning given in the introductory paragraph. 

“Foundation Investment” has the meaning given in the introductory paragraph. 

“Foundation Securities” has the meaning given in Section 5(c). 

“Foundation-supported Entity” means an entity selected by the Foundation for participation in a project that receives funding, directly or
indirectly, from the Foundation, collaborates with the Foundation, or both, for the purpose of accomplishing the Foundation’s charitable objectives. 

“Funded Developments” has the meaning given in Section 3(n)(i). 

“Global Access” means that (a) knowledge gained using the Foundation’s funding is promptly and broadly disseminated and
(b) the products and technologies developed or supported with the Foundation’s funding will be made available and accessible at an affordable price to people most in need in Developing Countries. 

“Global Access Commitments” has the meaning given in Section 3. 

“Global Health Assay Development Project” has the meaning given in Section 3(b). 

“Global Health License” has the meaning given in Section 3(n)(i). 

“Government Provisioned” has the meaning given in Section 3(g)(ii)(A). 

“Health Systems for Low Income People” has the meaning given in Section 3(g)(ii). 

 “HIV Viral Load Assay” has the meaning given in Section 3(d). 

“HIV Viral Load Assay Development Project” has the meaning given in Section 3(d). 

“HIV Viral Load Launch Project” has the meaning given in Section 3(e)(i). 

“Indemnitees” has the meaning given in Section 14. 

“Investment Documents” has the meaning given in the introductory paragraph. 

“Joint Steering Committee” has the meaning given in Section 3(k)(i). 

“Letter Agreement” has the meaning given in the introductory paragraph. 

“Low Income People” means those individuals living at or below the World Bank poverty line for lower-middle-income countries, which, at the
time of the execution of the Letter Agreement, is US$3.20 per day. 
 “Market Authorization” means appropriate authorization for
commercialization of the Products received from the relevant regulatory body. 
 “Note Investment” has the meaning given in the
introductory paragraph. 
 “Original Agreement” has the meaning given in the introductory paragraph. 

“Partner with Health Systems for Low Income People” has the meaning given in Section 3(g)(iii). 

“Platform Technology” means the Company’s research, development, clinical, regulatory, manufacturing, commercialization, service and
support, and distribution capabilities in respect of point-of-care diagnostic tests, integrated assays, reagents, software and instruments, and health IT and care
solutions. This may include, but is not limited to, technology related to the dissemination and/or storage and management of diagnostic results, associated patient-related data, and quality control related data (e.g. real-time instrument
functionality and controls) within health systems. The Platform Technology includes technologies, materials, know-how, intellectual property, and intellectual property rights owned, controlled, or in licensed
by the Company or its Affiliates, whether existing at closing or later developed, owned, controlled or in licensed by the Company or its Affiliates. 

“Point of Care Commercialization Project” has the meaning given in Section 3(a). 

“PPP/NGO Provisioned” has the meaning given in Section 3(g)(ii)(B). 

“Preferred Investment” has the meaning given in the introductory paragraph. 

“Private Sector Provisioned” has the meaning given in Section 3(g)(ii)(C). 

 “Product” means any diagnostic or other product or service developed pursuant to a Project.

 “Proof of Concept Grant” is the grant entered into between the Foundation and the Company on November 5, 2019. 

“Portfolio Manager” has the meaning given in Section 3(k)(ii). 

“Projects” means the Point of Care Commercialization Project, the Global Health Assay Development Project, the Fast Labs Project, the HIV
Viral Load Assay Development Project, the HIV Viral Load Assay Launch Project, the V7 Diagnostic Instrument Development Project, any Additional Project, and the Accelerated Commercialization Commitment. 

“Public Market Provision” means Government Provisioned and PPP/NGO Provisioned together. 

“Reasonable Efforts” means the level of effort the Company would expend in the development and commercialization of its lead commercial
product(s). 
 “Revised Agreement” has the meaning given in the introductory paragraph. 

“SOW” has the meaning given in Section 3(b). 

“Strategic Plan” has the meaning given in Section 3(d). 

“TPM” has the meaning given in Section 3(j)(ii). 

“TPP” has the meaning given in Section 3(b). 

“Trigger Event” has the meaning given in Section 3(n)(ii). 

“V7 Diagnostic Instrument” means a diagnostic instrument to be developed by the Company with the features set forth in the V7 Diagnostic
Instrument Target Product Profile that is low-cost, robust and appropriate for all clinical settings and intended to improve the access of people in Developing Countries to low cost point-of-care diagnostics, [***]. 
 “V7 Diagnostic Instrument Development
Plan” means the development plan for the V7 Diagnostic Instrument attached as Appendix J, as may be adjusted as part of the LMDX roadmap. 

“V7 Diagnostic Instrument Development Project” has the meaning given in Section3(h). 

“V7 Diagnostic Instrument Target Product Profile” means the target product profile for the V7 Diagnostic Instrument attached as
Appendix I. 
 “WHO Essential Diagnostics List” means the list attached as Appendix B. 

“WHO PQ” has the meaning given in Section 3(d). 

“Withdrawal Right” has the meaning given in Section 5(c). 

	2.	 Charitable Purpose; Use of Proceeds  

(a)    Charitable Purpose. The Foundation is making the Foundation Investment as a “program-related
investment” within the meaning of Section 4944(c) of the Code. The Foundation is committed to accelerating the development of lifesaving and low-cost drugs, therapeutics, diagnostics, and
prophylactics to reduce the burden of disease in developing countries in furtherance of its mission to help all people lead healthy, productive lives. The Foundation’s primary purpose in making the Foundation Investment is to secure Global
Access to new, low-cost products and services developed through the use of the Company’s proprietary capabilities and intellectual property, including in respect of (a) the commercialization of Point
of Care diagnostic tests in developing countries; (b) the development of a global health assay; and (c) the development and commercialization of third-party platform compatible diagnostic products and tests (collectively, the
“Charitable Purpose”). In furtherance of the Charitable Purpose, the Foundation Investment will secure the Global Access Commitments described below. 

(b)    Use of Proceeds. 

(i)    Preferred Investment. [***] million of the proceeds from the Preferred Investment were used solely to
fund the HIV Viral Load Assay Development Project and improvements in the Platform Technology in connection with the HIV Viral Load Assay Development Project in furtherance of the Charitable Purpose. The remaining [***] million of the proceeds from
the Preferred Investment was used solely to support the commercialization of the Platform Technology in Challenging Market Countries in accordance with the Accelerated Commercialization Commitment. 

(ii)    Note Investment. All proceeds of the Loan were used solely to fund the V7 Diagnostic Instrument Development
Project in furtherance of the Charitable Purpose. 
 (iii)    Equity Investment. [***] of the proceeds from the
Equity Investment will be used solely to fund the Point of Care Commercialization Project; [***] will be used solely to fund the Global Health Assay Development Project. The remaining [***] of the proceeds from the Equity Investment will be used
solely to fund the Company’s Fast Labs Project. 
 The proceeds from the Foundation Investment will not be required to be segregated in a separate
account nor required to be used for dedicated employees or facilities. 
  

	3.	 Global Access Commitments. 

In furtherance of the Charitable Purpose and Global Access, the Company agrees to the following (collectively “Global Access Commitments”):

 (a)    Point of Care Commercialization Project. The Company will support and expand its existing commitment to
Partner with Health Systems for Low Income People through [***] described in Section 3(g)(iii) below and engage in the Governance and Project Management activities described in Section 3(k), together the “Point of Care
Commercialization Project”. 

 (b)    Global Health Assay Development Project. The Company will
utilize the Platform Technology to develop through Market Authorization either: (i) [***] assay for [***] or (ii) a [***] assay; with a mutually agreed upon
Scope-of-Work (“SOW”) and Target Product Profile (“TPP”) between the Foundation and the Company ((i) and (ii) together, the
“Global Health Assay Development Project”). 
 (c)    Fast Labs Project. The Company will
utilize the Platform Technology to diligently develop according to a TPP mutually agreed upon between the Foundation and the Company and commercialize the Company’s [***] (the activities of which constitute the “Fast Labs
Project” with the resulting products the “Fast Labs Products”). 
 The additional Global Access Commitments
set forth in Sections 3(a), (b) and (c) above are in addition to and without prejudice to the existing Global Access Commitments under the Revised Agreement and restated below: 

(d)    HIV Viral Load Assay Development Project. The Company will diligently conduct the HIV Viral Load Assay
Development Project. “HIV Viral Load Assay Development Project” means (a) the Company’s development of an assay for HIV viral load (the “HIV Viral Load Assay”) in accordance with a mutually acceptable TPP
attached as Appendix C and SOW attached as Appendix D through World Health Organization Pre-Qualification (“WHO PQ”) and (b) the development of a manufacturing,
commercialization and distribution strategy (“Strategic Plan”) for delivery of point-of-care diagnostics within Developing Countries, including the HIV
Viral Load Assay, which strategy will include the elements set forth in, and be consistent with, the SOW for the HIV Viral Load Assay. 

(e)    HIV Viral Load Assay Launch Project. 

(i)    Once the HIV Viral Load Assay has been developed as described above, the Foundation will have the right, at its
discretion, to continue providing funding (directly or through a Foundation-supported Entity) to advance the HIV Viral Load Assay through commercialization and distribution of a final product in accordance with the Strategic Plan, HIV Viral Load
Assay TPP and a second mutually acceptable SOW (the “HIV Viral Load Launch Project”). The HIV Viral Load Assay Launch Project may include applicable development, commercialization and associated activities conducted by the Company
or partner(s) in accordance with the Strategic Plan or as otherwise agreed by the Company and Foundation, if and to the extent these activities are requested by the Foundation, including seeking applicable country-level regulatory approvals. If the
HIV Viral Load Assay Launch Project is requested by the Foundation, it would be co-funded by additional funding from the Foundation or a Foundation-supported Entity pursuant to the Foundation’s standard
funding terms and processes. The specific level and allocation of funding responsibilities between the parties (and potentially Foundation-supported Entities) for the HIV Viral Load Assay Launch Project will be mutually agreed in good faith in
writing by the parties to fairly allocate the expected benefits between Developing Countries and developed countries. 

(ii)    Any agreements for the HIV Viral Load Assay Launch Project will include a proposal describing the relevant work
(including specific global access commitments) and other related documents acceptable to the Foundation, and will be consistent with the HIV Viral Load Assay TPP. The applicable funding agreements will also include a license to the HIV Viral Load

 
Assay and related technology and intellectual property rights (including the right to sublicense or a direct grant to Foundation-supported Entities) that is exercisable in the event of a breach
of the Global Access Commitments related to the HIV Viral Load Assay Launch Project under the circumstances described below. 

(f)    Additional Projects. 

(i)    Additional Assay Projects. In addition to the Projects described above, if requested by the Foundation the
Company will utilize the Platform Technology to diligently conduct up to five Additional Assay Projects at the Foundation’s discretion and subject to the terms below. “Additional Assay Project” means a project proposed by the
Foundation or a Foundation- supported Entity and accepted and conducted by the Company utilizing the Platform Technology to develop an assay in accordance with a mutually agreed upon SOW and TPP, and potentially to further develop, commercialize,
and distribute such assays under a similar launch project construct. The parties agree that the five assays covered under the Proof of Concept Grant, which include: a TB Nucleic Acid Test, a sickle cell disease test and three tests for maternal and
antenatal care, exhaust all five Additional Assay Projects; provided that, the Foundation may propose additional projects (each an “Additional Project”) necessary to complete the Market Authorization and/or support the
commercialization of any of the Additional Assay Projects. 
 (ii)    Terms of Additional Projects. Each
Additional Project will be funded and conducted pursuant to the Foundation’s standard funding terms and processes, which would include a proposal prepared in good faith by the Company (which will be submitted within [***] after the
Foundation’s initial request to the Company) describing the relevant work to be conducted by the Company and other related documents acceptable to the Foundation. If the Foundation requests that the Company continue development and
commercialization of an assay developed through an Additional Assay Project, the Company will consider in good faith and the parties will negotiate in good faith the terms of the applicable grant documents for such work. To the extent the parties
agree to continue support of an Additional Project, the specific level and allocation of additional funding responsibilities for such Additional Project will be mutually agreed in good faith in writing by the parties based on a fair allocation of
the expected benefits between Developing Countries and developed countries. 
 (g)    Accelerated Commercialization
Commitment. 
 (i)    The Company will diligently conduct the Accelerated Commercialization Commitment as further
described below. “Accelerated Commercialization Commitment” means (A) the Company’s commitment to Partner with Health Systems for Low Income People and (B) the Company’s commitment to Align with Essential
Diagnostic List Market Coordination. 
 (ii)    The health systems serving Low Income People in Challenging Market
Countries are heterogenous and very different from those in the US and Europe. Often, they include the three archetype health delivery systems listed below. Each of these three health delivery systems operating in a Challenging Market Country is a
different “Archetype Health System” and collectively these three Archetype Health Systems are defined as “Health Systems for Low Income People.” 

 (A)    “Government Provisioned” means government
healthcare providers that are publicly owned and operated including community healthcare workers, primary and community health centers, district and regional health centers, government-run pharmacies and
diagnostic labs, and government-supported ambulance services. 
 (B)    “PPP/NGO Provisioned” means
public-private-partnerships or non-government organization providers of publicly or philanthropically owned and publicly or privately operated healthcare professionals operating community outreach programs
(e.g., Médecins Sans Frontières), or healthcare services in partnership with governments (e.g. public- private-partnership clinics for outpatient care). 

(C)    “Private Sector Provisioned” means providers that are privately owned and operated below
the tertiary care level, including individual or consolidated chains of primary care clinics, pharmacies, ambulances, and home-based care services. 

(iii)    The Company’s commitment to “Partner with Health Systems for Low Income People” consists of
the following: 
 (A)    During the [***], Health Systems for Low Income People will have [***]; 

(B)    During the [***], Health Systems for Low Income People will have [***]; 

(C)    During the [***], Health Systems for Low Income People [***]; and 

(D)    During the [***], Health Systems for Low Income People will [***]. 

(iv)    The Company’s commitment to “Align with Essential Diagnostic List Market Coordination”
consists of good-faith efforts to achieve the following: 
 (A)    The Company will [***]; 

(B)    The Company will [***]; and 

(C)    The Company will [***]. 

(v)    The Foundation understands that the achievement of the Accelerated Commercialization Commitments is dependent on
the cooperation and/or purchase commitments of third-parties and the Archetype Health System operators. In the event the Company is concerned that a lack of cooperation or commitment from Archetype Health System operators will make it impossible to
achieve one or more of the Accelerated Commercialization Commitments, the Company may request the Foundation to assist with discussions with such Archetype Health System operators and/or make other good-faith efforts to support the Company’s
commercialization efforts. Where Accelerated Commercialization Commitments require changes or alterations (which are not foreseen under the Company business plans) to the Platform Technology, instrument or assays to

 
adjust these for resource-poor settings or projects or specific delivery or service models, extensions to timelines may be required. In the event of such occurrence, the parties will discuss in
good faith and (A) the Accelerated Commercialization Commitments may be modified; or (B) the Foundation may provide additional funding for such project to achieve the Accelerated Commercialization Commitments, each of (A) and (B) at
the sole discretion of the Foundation. 
 (h)    V7 Diagnostic Instrument Development Project. The Company will
utilize the Platform Technology to diligently develop the V7 Diagnostic Instrument and assays thereon through commercialization no later than [***] (“V7 Diagnostic Instrument Development Project”). The V7 Diagnostic Instrument will
be developed in accordance with the V7 Diagnostic Instrument Development Plan. As part of the V7 Diagnostic Instrument Development Project, the Company will use Reasonable Efforts to achieve the COGS goals set forth in the V7 Target Product Profile.
The Company will provide the Foundation with documentation in the form of copies of invoices, relevant regulatory filings and/or clearances, certified cost of goods statements and other documents that may be requested by the Foundation to
demonstrate COGS of the V7 Diagnostic Instrument. 
 (i)    Receipt and Continuation of Licenses. The Foundation
Investment will be conditioned on the Company’s receipt and continuation of all necessary licenses and rights with respect to the Platform Technology needed to perform the Global Access Commitments. 

(j)    Pricing and Volume Commitments. 

(i)    The Company agrees to make available to Low Income People in Developing Countries any Products developed and
commercialized pursuant to the HIV Viral Load Assay Development Project, HIV Viral Load Assay Launch Project, any Additional Assay Project, the Global Health Assay Development Project, and the Fast Labs Project (a) at or below the price set
forth in the applicable TPP and (b) in quantities meeting or exceeding those set forth in the applicable SOW (or other applicable global access agreements between the Foundation and the Company). Additionally, other Products developed and
distributed by the Company will be commercialized in Challenging Market Countries consistent with the maximum pricing and capacity reservation schedule included in Appendix E. In the event that the Foundation notifies the Company of the
Foundation’s concerns that the affordability and availability intent of Global Access is being violated in a specific Challenging Market Country, the parties agree to work together in good faith to rectify the concern to the satisfaction of the
Foundation. These commitments do not apply to sales of Products used outside of the Developing Countries. 

(ii)    Third party manufacturing. If the Foundation reasonably determines that the Company is unlikely to achieve prices
and volumes for the HIV Viral Load Assay or a Fast Labs Product that are within [***] of the applicable maximum price and minimum volume commitments and that a third-party manufacturer (“TPM”) would likely be able to meet such price
and volume commitments, the Foundation will notify the Company of such determination and provide a summary of the reasons for such determination in reasonable detail. During the [***] period following delivery of such notice, the parties will engage
in good-faith discussions regarding the Company’s ability to achieve the applicable price and volume commitments, its plan for doing so (if applicable) and (if applicable) the reasons why a TPM may not be able to achieve such applicable price
and volume commitments either. If the parties are unable to come to an agreement regarding a plan for the Company to achieve the applicable price and volume commitments for the HIV Viral 

 
Load Assay or Fast Lab Product, in order to advance the Charitable Purpose the Company will license and transfer the necessary intellectual property and technology to such TPM (subject to such
TPM entering into reasonable agreements with the Company regarding confidentiality and use of the technology and licenses solely for the purposes contemplated herein) in order to allow the production, testing, approval, and distribution of the HIV
Viral Load Assay or Fast Lab Product for the Developing Countries at such committed lower pricing. The Foundation will be responsible for the reasonable costs payable for the transfer of the necessary technology to such TPM. 

(iii)    V7 Diagnostic Instrument. The Company will make the V7 Diagnostic Instrument available to serve Low Income
People in Challenging Market Countries at an affordable price that is no greater than the maximum price and in at least the minimum volumes set forth in the V7 Target Product Profile. These commitments do not apply to sales of products used outside
of Challenging Market Countries or not targeting Low Income People. 
 (k)    Governance and Project Management.

 (i)    Joint Steering Committee. The parties will each designate three individuals who are subject matter
experts to be part of a joint steering committee (the “Joint Steering Committee”) that provides a forum for discussion of the progress of the (a) Platform Technology (b) the Projects and (c) any other activities with
the Foundation including existing and future grants. It is agreed by the Parties that one of the individuals designated by the Company will be [***]. Certain key decisions of the Joint Steering Committee related to advancing to the next phase of
development (as outlined in the existing and future SOW) will require the affirmative vote of the individuals designated by the Foundation. The Joint Steering Committee will meet via teleconference monthly through [***], at least once quarterly
after that via teleconference and at least once annually in-person. With the agreement of both parties and subject to the execution of appropriate confidentiality agreements, third-parties may be invited from
time to time to participate in certain Joint Steering Committee discussions, it being understood that the Company may object if competitive sensitive information would be released to one of its competitors. Furthermore, the Company will track and
circulate to the Joint Steering Committee a dashboard report that will initially include the items noted in Appendix F and other information that the Joint Steering Committee identifies as important to achieve this commitment. 

(ii)    Portfolio Manager. The Company will specifically appoint an employee whose sole responsibility is
(i) ensuring the Company achieves its commitments to the Foundation (including Platform Technology development, Projects and any other activities with the Foundation including existing and future grants); and (ii) providing real-time
reporting on the progress against those commitments to the Foundation (including but not limited to monthly meetings with Foundation representatives and quarterly submission of detailed written reports to the Foundation). 

(iii)    Additional Communications. In addition, if requested by the Foundation, members of the Company’s
technical team will meet with Foundation programmatic representatives at least once quarterly via teleconference or onsite visits at Company facilities to provide an update on any of the Projects, with such updates to provide a level of detail
sufficient to assess the status of such Projects against the applicable SOW and TPPs (as applicable). 

 (l)    Publication; Access to Data and Information. The Company
will (in addition to the publication requirements of any other agreements with the Foundation):  

(i)    publish the results and information developed in connection with each Project within a reasonable period of time
after such information or results are obtained, subject to reasonable delays or limitations on content of such publications that are necessary to protect intellectual property and trade secrets covering the Platform Technology itself. All
publications must be made in accordance with “open access” terms and conditions consistent with the Foundation’s Open Access Policy (available at: http://www.gatesfoundation.org/How-We-
Work/General-Information/Open-Access-Policy), which may be modified from time to time; 
 (ii)    promptly provide to
the Foundation from time to time, upon the Foundation’s request, access to data and information regarding the Projects, the reasonably contemplated use of the Platform Technology for such Projects, and the considerations made by the Company
with respect to accessibility, affordability and cost effectiveness; and 
 (iii)    promptly provide to the Foundation
from time to time, upon the Foundation’s request, rights to share such data and information regarding the Projects, and the reasonably contemplated use of the Platform Technology for the Projects, subject to the reasonable need to protect
confidential information and to avoid untimely public disclosures that may bar access to patent protection or public disclosures that may undermine trade secret protection. 

(m)    No Inconsistent Rights. The Company will not grant to a third-party any rights or enter into any
arrangements or agreements that would limit or restrict the Foundation’s rights to the Global Access Commitments. 

(n)    Global Health License. 

(i)    Global Health License. In connection with and relating to the Projects (other than any Additional Project
that has not yet resulted in a product that was funded by the Foundation and sold in a Challenging Market Country), the Company hereby grants the Foundation and/or Foundation-supported Entities a worldwide,
non-exclusive, non-terminable, perpetual, royalty-free license (with the right to sublicense) to the products, technologies, materials, processes, and other intellectual
property and intellectual property rights developed using funds from the Foundation or a Foundation-supported Entity or developed in connection with the Company’s conduct of such Projects (the “Funded Developments”) and the
background intellectual property of the Company that covers or is used in the Platform Technology and/or such Projects to use, reproduce, modify, make, distribute, sell,
offer-for-sale, import, and otherwise dispose of diagnostic products and services directed at pathogens or diseases that disproportionately affect people in Developing
Countries in a manner consistent with the Foundation’s Charitable Purpose (“Global Health License”). The Global Health License is a presently granted license. The Foundation will not exercise the Global Health License except in
the event of a Trigger Event and Foundation’s rights upon exercise of such Global Health License will extend only to the Product or Project from which the Trigger Event arises and only in furtherance of the Foundation’s Charitable Purpose.
In the event of a Trigger Event that applies only to a particular Product or Project, the Foundation will have the right to exercise the Global Health License (and the Company will have the obligation to take the further actions described in the
following subsection (o) only for such Product or Project. For avoidance of doubt, Additional Projects that result in products funded by the Foundation and sold in one or more Challenging Market Countries shall be subject to the Global Health
License which shall be exercisable only in the event of a Trigger Event. 

 (ii)    Trigger Events. The Foundation will not exercise its
rights under the Global Health License (including its sublicensing rights) unless at least one of the following occurs (each, a “Trigger Event”): 

(A)    a Charitability Default that remains uncured for 120 days following written notice by either party of such
Charitability Default; or 
 (B)    the Company (1) institutes any bankruptcy, insolvency, appointment of a
receiver and/or trustee or reorganization (in either case for the release of financially distressed debtors), general assignment for the benefit of creditors, winding-up, dissolution, liquidation or similar
proceeding relating to it under the laws of any jurisdiction or any such proceeding is instituted against the Company which remains undismissed or unstayed for a period of [***] or (2) ceases to conduct business in the ordinary course or is
determined to no longer be a going concern. 
 If either the Foundation or the Company becomes aware of a Trigger Event, it will promptly
notify the other party in writing of the occurrence of such Trigger Event. 
 (o)    Cooperation; Technology
Transfer. In connection with the exercise of any license hereunder the Company will take further actions, including technology transfer (subject to appropriate confidentiality obligations), as would be commercially reasonable industry practice
at the time with respect to providing a biotechnology license to a third party, to accommodate that the Foundation, the Foundation’s sublicensees, and/or the relevant Foundation-supported Entity can effectively exercise the applicable Global
Health License and use the related technology and manufacture the relevant Products if a Trigger Event occurs (including the right to reference regulatory filings related to the applicable Products), in each case solely as permitted under the Global
Health License. Notwithstanding the foregoing, the technology transfer obligations described above will not apply with respect to the Company’s confidential manufacturing processes or technologies related to its Delta ModTech manufacturing
line(s) so long as, if requested by the Foundation, the Company enters into and performs its obligations under a supply agreement with the Foundation or a Foundation-supported Entity for the manufacture of the applicable funded product at a price
that does not exceed the Company’s cost of goods (Ex-Works) sold plus [***] and subject to other terms that are reasonably acceptable to the parties. 

(p)    Intellectual Property Rights. The Company represents and covenants that the Company has and will continue to
have all necessary rights to the Platform Technology (including all rights in any patents, copyrights, trademarks, trade secrets, data, confidential information, know-how, and other intellectual property or
proprietary right) needed to perform the Global Access Commitments and grant the licenses hereunder. 

(q)    Duration of Global Access Commitments. The Global Access Commitments will be ongoing and will continue for
as long as the Foundation exists, except that the price and volume commitments set forth in Section 3(j)(iii) in respect of the V7 Diagnostic Instrument, or successor instrument, will expire [***] following the first commercial launch of the V7
Diagnostic Instrument in a Challenging Market Country. 

	4.	 Survival of Global Access Commitments. 

In the event of (i) an Acquisition Transaction, or (ii) the sale, exclusive license, or other transfer of the Platform Technology
owned or controlled by the Company or the Funded Developments, the Global Access Commitments will survive and be assumed in full by the purchaser, transferee, licensee, or acquirer and the Company will take all action necessary to ensure such
assumption. The Foundation will have the right to review the provisions of the written agreement with such third-party that relate to the assumption of the Global Access Commitments to confirm that the Global Access Commitments will survive and be
assumed by the third-party and will continue to be directly enforceable by the Foundation. For clarity, notwithstanding anything to the contrary in this Letter Agreement, the Foundation’s rights hereunder that exist on the date of the
Acquisition Transaction or sale, exclusive license, or other transfer of the Platform Technology or the Funded Developments will not be terminated by such transaction. 

In addition, at the earlier to occur of (a) the agreement by the Company with a third party on the key terms of an Acquisition
Transaction or (b) [***] prior to the closing of an Acquisition Transaction, the Company will provide the Foundation with written notice of the proposed Acquisition Transaction. The Company will also work in good faith with the Foundation and the
proposed acquirer to develop and agree to (prior to the closing of such Acquisition Transaction) a written plan that is acceptable to the Foundation that provides adequate assurances of the continued performance and timely transition of the Global
Access Commitments. Among other things, the plan will describe the resource commitments and timeline to support the transition and will provide that the personnel responsible for performance of the Global Access Commitments will have a level of
knowledge and experience that is appropriate for such performance. Upon approval of the plan by the Foundation, the plan will become part of the Global Access Commitments and will be binding on the Company and acquirer. 

 

	5.	 Withdrawal Right. 

(a)    The Withdrawal Right described and defined in this Section 5 will be triggered only as a result of a
Charitability Default. 
 (b)    A “Charitability Default” means that the Company
(i) is in material breach of any of the Global Access Commitments, including the failure to conduct the Projects as described herein, other than for reasons of technical or scientific failure not within the control of the Company and not known
to the Company at or before closing of each Foundation Investment, (ii) fails to comply with the restrictions in Sections 2 and 9 of this Letter Agreement on the use of proceeds from the Foundation Investment, or (iii) fails to comply with
the other related U.S. legal obligations set forth in this Letter Agreement, including the requirements set forth in Sections 6, 9, 11, and 12. Each party agrees to promptly notify the other party in writing if it becomes aware of a Charitability
Default and the Company will thereafter promptly provide to the Foundation a proposed strategy to remedy the Charitability Default. Notwithstanding the foregoing, the Foundation will not lose any rights or remedies solely as a result of a failure to
notify the Company after it becomes aware of a Charitability Default. 

 (c)    If the Company fails to cure the Charitability Default within 120
days of the Foundation’s written notice of such Charitability Default, and if the Foundation holds any securities of the Company, including securities issued in respect of or upon conversion or exercise of such securities (collectively, the
“Foundation Securities”) or any loans from the Foundation are outstanding, in each case issued or extended in connection with the Foundation Investment, the Company will have the obligation, if requested by the Foundation, to
(i) redeem all of the Foundation Securities or locate a third-party that will purchase the Foundation Securities and (ii) to repay the entire unpaid principal and accrued and unpaid interest on such loans without presentment, demand,
protest or notice of any kind, all of which are expressly waived ((i) and (ii), the “Withdrawal Right”). If the Company is unable to redeem all of the Foundation Securities, and no third party purchases the Foundation Securities, then the
Company will use its best efforts to effect the Withdrawal Right, consistent with the Code and applicable law, as soon as practicable. During any period when the Company is unable to exercise its obligations with respect to the Withdrawal Right, the
Company will not pay dividends on any of its capital stock, redeem the capital stock of any other stockholder of the Company (excluding repurchases of stock from former employees, officers, directors, consultants or other persons who performed
services for the Company or any subsidiary in connection with the cessation of such employment or service at the lower of the original purchase price or the then-current fair market value thereof) or otherwise make any other distribution to any
other stockholder of the Company (other than shares of common stock or stock options issued to employees or directors of, or consultants or advisors to, the Company or any of its subsidiaries pursuant to a plan, agreement or arrangement approved by
the Board of Directors of the Company). The Company’s obligations in connection with the Withdrawal Right will be subordinate to the Company’s repayment obligations with respect to the Senior Indebtedness (as defined in the Note
Investment). 
 (d)    For redemption or purchase by the Company or a third-party pursuant to Section 5(c), the
Foundation Securities will be valued at the greater of (i) the original purchase price attributable to such shares plus a [***] per annum compounding interest rate calculated from the date of issuance of the Foundation Securities through the
date of redemption or purchase or (ii) Fair Market Value. 
 (e)    Notwithstanding any exercise of the Withdrawal
Right by the Foundation, the Foundation’s rights under the Global Access Commitments will survive. 
  

	6.	 Required Reporting; Audit Rights. 

(a)    In addition to reports required to be delivered to the Foundation under the Investment Documents, the Company will
furnish, or cause to be furnished, to the Foundation the following reports and certifications: 
 (i)    within [***]
after the end of each of the Company’s fiscal years during which the Foundation owns any securities in the Company, a certificate from the Company signed by an officer of the Company and substantially in the form attached to this Letter
Agreement as Appendix G, certifying that the requirements of the Foundation Investment set forth in this Letter Agreement were met during the immediately preceding fiscal year, describing the use of the proceeds of the Foundation Investment
and evaluating the Company’s progress toward achieving the Global Access Commitments; 

 (ii)    within [***] after the end of the Company’s fiscal year
during which the Foundation ceases to own any securities in the Company, a certificate from the Company signed by an officer of the Company and substantially in the form attached to this Letter Agreement as Appendix H, certifying that the
requirements of the Foundation Investment set forth in this Letter Agreement were met during the term of the Foundation Investment, describing the use of the proceeds of the Foundation Investment and evaluating the Company’s progress toward
achieving the Global Access Commitments; 
 (iii)    any other information respecting the operations, activities and
financial condition of the Company as the Foundation may from time to time reasonably request to discharge any expenditure responsibility, within the meaning of Sections 4945(d)(4) and 4945(h) of the Code, of the Foundation with respect to the
Foundation Investment, and to otherwise monitor the charitable benefits intended to be served by the Foundation Investment. The Foundation will reimburse the Company for any reasonable third-party expenses incurred by the Company in order to prepare
any information the Company is required to prepare solely as a result of this Section 6(a)(iii); and 

(iv)    full and complete financial reports of the type ordinarily required by commercial investors under similar
circumstances to the extent required pursuant to Treasury Regulation 53.4945-5(b)(4). 

(b)    At the Foundation’s reasonable request, the Company will provide the Foundation with a summary of scientific
data and progress to date on all Projects and any Platform Technology related to the foregoing, and the considerations made by the Company with respect to accessibility, affordability and cost-effectiveness of the applicable Products for people and
payors in Developing Countries, in addition to the information that may be required under any grant agreements or other funding agreements. 

(c)    Without limiting the foregoing, at the Foundation’s request, the Company will permit the Foundation or its
representatives to inspect (at a reasonable time and location) the scientific records of the Company relating to each Project with due regard to the reasonable need to protect trade secrets covering the Platform Technology. 

(d)    The Company will maintain books and records adequate to provide information ordinarily required by commercial
investors under similar circumstances, including accounting records and copies of any reports submitted to the Foundation related to each Project. The Company will retain such books, records, and reports for four years after the Foundation ceases to
hold Company securities and will make such books, records, and reports available to the Foundation at reasonable times to enable the Foundation to monitor and evaluate how the Foundation’s funds have been used. 

(e)    The Company will permit employees or agents of the Foundation at any reasonable time and upon reasonable prior
notice, during normal business hours, to examine or audit the Company’s books and accounts of record and to make copies and memoranda of the same, in each case at the Foundation’s expense to audit the Company’s compliance with the use
of the Foundation Investment and the Global Access Commitments. If the Company maintains any records (including 

 
computer-generated records and computer software programs for the generation of such records) in the possession of a third party, the Company, upon request of the Foundation, will notify such
party to permit the Foundation free access to such records at all reasonable times and to provide the Foundation with copies of any records it may reasonably request in connection with such audit, request or inquiry, all at the Foundation’s
expense. 
  

	7.	 Gender Diversity and Board Observer. 

The Company will on a best efforts basis maintain gender diversity in its organization, including amongst the board of directors, senior
management team and employee workforce (the “Commitment to Gender Diversity”). In this regard, the Company will present its key gender diversity metrics, initiatives, and progress to the Company’s board of directors on a
periodic basis (half-yearly, at minimum) for review and discussion. 
 In addition to the Foundation’s right to appoint a director to
the Company’s Board of Directors (as set forth in the other Investment Documents), as long as the Foundation or an Affiliate thereof owns any Foundation Securities, the Foundation shall be entitled to designate one person to attend all meetings
of the Company’s Board of Directors and committees thereof in a nonvoting observer capacity and the Company shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the
same time and in the same manner as provided to such directors; provided that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or
attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in a potential conflict of interest on the part of the Foundation. 

 

	8.	 Assignment. 

Notwithstanding anything in this Letter Agreement or any Investment Document to the contrary, the Foundation will have the right to assign this
Letter Agreement or transfer the Foundation Securities to (a) any successor charitable organization of the Foundation from time to time that is a tax exempt organization as described in Section 501(c)(3) of the Code, or (b) any tax
exempt organization as described in Section 501(c)(3) of the Code controlled by one or more trustees of the Foundation. The Foundation will notify the Company of any such assignment, including the identity of the assignee, in a timely manner.
For the avoidance of doubt, if the Foundation transfers the Foundation Securities as permitted by this Section 8, the Foundation may assign to any such transferee all of its rights attached to such Foundation Securities, including the
Withdrawal Right. 
  

	9.	 Prohibited Uses. 

The Company will not expend any proceeds of the Foundation Investment to carry on propaganda or otherwise to attempt to influence legislation,
to influence the outcome of any specific public election or to carry on, directly or indirectly, any voter registration drive, or to participate or intervene in any political campaign on behalf of or in opposition to any candidate for public office
within the meaning of Section 4945(d) of the Code. The proceeds of the Foundation Investment will not (a) be earmarked to be used for any activity, appearance or communication associated with the

 
activities described in the foregoing sentence, nor (b) be intended for the direct benefit, and will not benefit, any person having a personal or private interest in the Foundation,
including descendants of the founders of the Foundation, or persons related to or controlled by, directly or indirectly, such private interests. 

For the avoidance of doubt, the Company will not use the funds received from the Foundation to pay a dividend or redeem shares. 

 

	10.	 Disqualified Person. 

Neither the Company nor (to the best knowledge of the Company) any stockholder of the Company is a “disqualified person” with respect
to the Foundation (as the term “disqualified person” is defined in Section 4946(a) of the Code). The Foundation does not, and one or more disqualified persons with respect to the Foundation do not, directly or indirectly, control the
Company. 
  

	11.	 Anti-Terrorism. 

The Company will not use any portion of the Foundation Investment, directly or indirectly, in support of activities (a) prohibited by U.S.
laws related to combatting terrorism; (b) with persons on the List of Specially Designated Nationals (www.treasury.gov/sdn) or entities owned or controlled by such persons; or (c) with countries or territories against which the U.S.
maintains comprehensive sanctions (currently, Cuba, Iran, Syria, North Korea, and the Crimean Region and so-called Luhansk and Donetsk People’s Republics of Ukraine), unless such activities are fully
authorized by the U.S. government under applicable law and specifically approved by the Foundation in its sole discretion. 
  

	12.	 Anti-Corruption and Anti-Bribery. 

The Company will not offer or provide money, gifts, or any other things of value directly or indirectly to anyone in order to improperly
influence any act or decision relating to the Foundation or any activities contemplated by this Letter Agreement or the Company’s organizational documents (e.g., certificate of incorporation or articles of association), including by assisting
any party to secure an unlawful advantage. Training and information on compliance with these requirements are available at www.learnfoundationlaw.org. 
  

	13.	 Public Reports; Use of Name. 

The Foundation may include information on this investment in its periodic public reports and may make the investment public at any time on its
web page and as part of press releases, public reports, speeches, newsletters and other public document, and to the extent required by applicable law or regulation. Any announcement of the Foundation Investment by any other party, including the
Company, its representatives, directors, stockholders and agents, or any investor, will require the Foundation’s prior written approval. Such parties will also obtain the Foundation’s prior written approval for any other use of the
Foundation’s name or logo in any respect; provided, however, that the Company may use the Foundation’s name for any uses that have been pre- approved in writing

 
by the Foundation. Notwithstanding the foregoing, the Foundation’s name and logo will not be used by any party in any manner to market, sell or otherwise promote the Company, its products,
services and/or business. 
  

	14.	 Indemnification. 

The Company will indemnify, hold harmless, and defend the Foundation and its co-chairs, trustees,
directors, officers, employees, agents, and representatives (collectively, the “Indemnitees”) from and against any and all third party causes of action, claims, suits, legal proceedings, judgments, settlements, damages, penalties,
losses, liabilities and costs (including reasonable attorneys’ fees and costs) (each a “Claim”) finally awarded to such-third party by a court of competent jurisdiction against any of the Indemnitees or agreed to as part of a
monetary settlement of the Claim and arising out of or relating to: (a) bodily injury, death or property damage caused by the activities or omissions of the Company, including any development or commercialization or distribution activities
carried out by the Company (including any failure to comply with applicable laws, regulations or rules in connection therewith), or by any product; or (b) any Claim that the Platform Technology, any Funded Development or any product infringes
upon a patent, proprietary, or other intellectual property right of a third-party. The Foundation will give the Company prompt written notice of any Claim subject to indemnification; provided, that the Foundation’s failure to promptly notify
the Company will not affect the Company’s indemnification obligations except to the extent that the Foundation’s delay prejudices the Company’s ability to defend the Claim. The Company will have sole control over the defense and
settlement of each and every Claim, with counsel of its own choosing which is reasonably acceptable to the Foundation; provided, that the Company conducts the defense actively and diligently at the sole cost and expense of the Company and provided
further that the Company will not enter into any settlement that adversely affects any Indemnitee without the applicable Indemnitee’s prior written consent, such consent not to be unreasonably withheld, conditioned or delayed. The Foundation
will provide the Company, upon request, with reasonable cooperation in connection with the defense and settlement of the Claim. Subject to the Company’s rights above to control the defense and settlement of Claims, the Foundation and any
Indemnitee may, at its own expense, employ separate counsel to monitor and participate in the defense of any Claim under this Section 14. 

The parties will not be liable to each other for any indirect, incidental, consequential, or special damages (including lost revenues, lost
savings, or lost profits suffered by such other party) suffered by such other party arising under or in connection with this Letter Agreement, regardless of the form of action, whether in contract or tort, including negligence of any kind, whether
active or passive, and regardless of whether the party knew of the possibility that such damages could result; provided, that to the extent an Indemnitee is entitled to be indemnified hereunder for Claims of third parties and such third party has
been awarded indirect, incidental, consequential, reliance, or special damages (including lost revenues, lost savings, or lost profits), the Company’s indemnification obligations to the Indemnitee will extend to and include such third
party’s indirect, incidental, consequential, reliance, or special damages (including lost revenues, lost savings, or lost profits). The parties further agree that under no circumstances will any party be liable to the other party (or to any
Indemnitee) more than once for the same losses arising under or in connection with this Letter Agreement. 

	15.	 Insurance. 

The Company agrees to maintain insurance coverage sufficient to cover the activities, risks, and potential omissions in respect of the Projects
in accordance with generally-accepted industry standards and as required by law. The Company will ensure all subcontractors maintain insurance coverage consistent with this paragraph. 

 

	16.	 Compliance with Laws and Requirements; Responsibility. 

The Company will comply with all applicable laws and regulations, including intellectual property laws. The Company will conduct, control,
manage, and monitor the Projects in compliance with all applicable ethical, legal, regulatory, and safety requirements, including applicable international, national, local, and institutional standards. The Company will obtain and maintain all
necessary approvals, consents, and reviews before conducting the applicable activity. If a Project involves: 

(a)    any protected information (including personally identifiable, protected health, or third party confidential), the
Company will not disclose this information to the Foundation without obtaining the Foundation’s prior written approval and all necessary consents to disclose such information; 

(b)    children or vulnerable subjects, the Company will obtain any necessary consents and approvals unique to these
subjects; or 
 (c)    any trial involving human subjects, the Company will adhere to current Good Clinical Practice as
defined by the International Council on Harmonisation (ICH) E-6 Standards (or local regulations if more stringent) and will obtain applicable trial insurance. 

The Company will be solely responsible and liable for all activities related to the conduct of the Projects. For avoidance of doubt, as
between the Foundation and the Company, the Company will have responsibility for all clinical trials. Any activities by the Foundation in reviewing documents and providing input or funding do not modify the Company’s responsibility, including
responsibility for determining and complying with the provisions of this Section 16. 
  

	17.	 Entire Agreement; Modification. 

The terms and conditions set forth in this Letter Agreement are in addition to the provisions stated in the other Investment Documents and the
terms and conditions of this Letter Agreement will prevail over any inconsistent provision in any other Investment Document. No change, modification or waiver of any term or condition of this Letter Agreement will be valid unless it is in writing,
it is signed by the party to be bound, and it expressly refers to this Letter Agreement. 
  

	18.	 Authority; Governing Law. 

Each of the signatories below covenants, represents and warrants that he, she or it had all authority necessary to execute this Letter
Agreement and that, on execution, this Letter Agreement will be fully binding and enforceable in accordance with its terms, and that no other consents or 

 
approvals of any other person or third parties are required or necessary for this Letter Agreement to be so binding. This Letter Agreement will be governed by the laws of England and Wales,
excluding its conflicts of laws provisions. 
  

	19.	 Counterparts. 

This Letter Agreement may be executed in one or more counterparts, each of which will be deemed an original, but all of which will be deemed to
be and constitute one and the same instrument. 
  

	20.	 Construction. 

Section headings are not to be considered part of this Letter Agreement, are included solely for convenience, are not intended to be full or
accurate descriptions of the content thereof, and will not effect the construction of this Letter Agreement. The words “include,” “includes” and “including” will be considered to be followed by the words “without
limitation”.EX-10.25

 Exhibit 10.25 

Portions of this Exhibit have been redacted because they are both (i) not material and (ii) are the type that the registrant treats as private or
confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. 

ROYALTY AGREEMENT 

between 
 LUMIRADX
LIMITED 
 and 

USB FOCUS FUND LUMIRADX 2A, LLC 

and 
 USB FOCUS FUND
LUMIRADX 2B, LLC 
 and 

PACIFIC PREMIER TRUST CUSTODIAN FBO WILLARD L. UMPHREY ROTH IRA 

and 
 PACIFIC
PREMIER TRUST CUSTODIAN FBO LEON OKUROWSKI ROTH IRA 
 and 

PEAR TREE PARTNERS, L.P. 

27 April, 2022 

 TABLE OF CONTENTS 

 

							
	 	  	 	 	Page Nos.	 
			
	1.	  	DEFINITIONS AND INTERPRETATION	 	 	3	 
	2.	  	PAYMENT OF THE INVESTED AMOUNT	 	 	12	 
	3.	  	ROYALTY PAYMENT	 	 	13	 
	4.	  	REPORTS	 	 	17	 
	5.	  	AUDIT	 	 	18	 
	6.	  	CLOSING	 	 	19	 
	7.	  	WARRANTIES	 	 	20	 
	8.	  	CONFIDENTIALITY	 	 	21	 
	9.	  	ANNOUNCEMENTS	 	 	23	 
	10.	  	NOTICES	 	 	24	 
	11.	  	FURTHER ASSURANCES	 	 	24	 
	12.	  	COSTS, EXPENSES AND TAXES	 	 	24	 
	13.	  	ASSIGNMENT	 	 	25	 
	14.	  	VARIATION	 	 	25	 
	15.	  	RIGHTS OF THIRD PARTIES	 	 	25	 
	16.	  	ENTIRE AGREEMENT	 	 	25	 
	17.	  	REMEDIES	 	 	26	 
	18.	  	WAIVER	 	 	26	 
	19.	  	SEVERANCE	 	 	26	 
	20.	  	COUNTERPARTS AND DUPLICATES	 	 	26	 
	21.	  	GOVERNING LAW AND JURISDICTION	 	 	27	 
	SCHEDULE 1 - INITIAL INVESTED AMOUNT	 			
	SCHEDULE 2 - SUBSEQUENT INVESTMENT NOTICE	 			

  
 ii 

 This royalty agreement (the “Agreement”) is entered into on 27 April 2022. 

BETWEEN 
  

	(1)	 LUMIRADX LIMITED, an exempted company with limited liability incorporated in the Cayman Islands under
company number 314391 whose registered office is at Ocorian Trust (Cayman) Limited, PO Box 1350, Windward 3, Regatta Office Park, Grand Cayman KY1-1108, Cayman Islands (the “Company”);

  

	(2)	 USB FOCUS FUND LUMIRADX 2A, LLC, a Delaware limited liability company, whose registered office is at 55
Old Bedford Road, Lincoln, Massachusetts 01773 (“Focus Fund I”); 

  

	(3)	 USB FOCUS FUND LUMIRADX 2B, LLC, a Delaware limited liability company, whose registered office is at 55
Old Bedford Road, Lincoln, Massachusetts 01773 (“Focus Fund II”);  

  

	(4)	 PACIFIC PREMIER TRUST CUSTODIAN FBO WILLARD L. UMPHREY ROTH IRA (the “Umphrey
Vehicle”); 

  

	(5)	 PACIFIC PREMIER TRUST CUSTODIAN FBO LEON OKUROWSKI ROTH IRA (the “Okurowski Vehicle”
and, collectively with Focus Fund I, Focus Fund II, and the Umphrey Vehicle, the “Investors”); and 

  

	(6)	 PEAR TREE PARTNERS, L.P., a Delaware limited partnership, whose registered office is at 55 Old Bedford
Road, Lincoln, Massachusetts 01773, in its capacity as the Investor Representative hereunder (“PTP”); 

 each a
“Party” and together the “Parties”. 
 WHEREAS 

 

	(A)	 The Company is engaged in the research, development and commercialization of a novel proprietary point-of-care diagnostic platform (the “LumiraDx POC Platform”). 

  

	(B)	 The Company proposes to manufacture up to 20,000 additional New Instruments (as defined herein) and the
Investors have agreed to make an investment in the Company in an amount equal to the Invested Amount (as defined herein) to enable the Company to manufacture such New Instruments. 

 

	(C)	 In consideration of the Investors paying such Invested Amount to the Company on the terms set forth herein, the
Company desires to pay to the Investors a royalty on the sale of Test Strips (as defined herein) used in such New Instruments under the terms and subject to the conditions set forth herein. 

NOW THEREFORE, for and in consideration of the covenants, conditions, and undertakings hereinafter set forth, it is agreed by and between the parties
as follows: 
  

	1.	 DEFINITIONS AND INTERPRETATION 

Definitions 
  

	1.1	 In this Agreement, unless the context requires otherwise, the capitalised terms set out below have the
following meanings: 

 “$” or “US Dollars” means United States dollars, being the lawful
currency for the time being of the United States of America; 

  
 3 

 “Additional Royalty Shortfall” means an amount, expressed in US Dollars,
equal to: 
  

	 	a)	 for the purposes of Clause 3.5(a), the product of the Initial True Up Shares and the Initial Share Price
Difference; and 

  

	 	b)	 for the purposes of Clause 3.10(a), the product of the applicable Subsequent True Up Shares and the applicable
Subsequent Share Price Difference; 

 “Affiliate” means, with respect to any Person, any other Person
that, directly or indirectly, controls, is controlled by or is under common control with such Person or, to the extent applicable, a Family Relative of such Person. For the purposes of this definition, “control” of a Person means
the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such Person, whether through the ownership of securities entitled to elect the board of directors or management board, by
contract or otherwise, and the terms “controlled” and “controlling” have meanings correlative to the foregoing; 

“Allocated” has the meaning set out in Clause 2.6; 

“Applicable Law” means, with respect to any Person, all Laws, rules, regulations and orders of governmental authorities
applicable to such Person or any of its properties or assets; 
 “Articles of Association” means the articles of association
of the Company in force from time to time; 
 “Board” means the board of directors for the time being of the Company or a
committee of such board duly authorized to act on behalf of such board; 
 “Business Day” means a day (excluding Saturdays)
on which banks generally are open in London and New York City for the transaction of normal banking business; 
 “Capital
Lease” means, as applied to any Person, any lease of, or other arrangement conveying the right to use, any property by that Person as lessee that has been or should be accounted for as a capital lease on a balance sheet of such Person; 

“Common Shares” means the common shares of US$0.0000028 each in the share capital of the Company, listed under the trading
symbol “LMDX” on The Nasdaq Global Market and having the rights set out in the Articles of Association; 

“Company” has the meaning set forth in recital (1); 

“Company Account” means: 
  

			
	 ABA Routing Number:
	  	[***]
		
	 Beneficiary Account Name:
	  	[***]
		
	 SWIFT Code:
	  	[***]
		
	 Beneficiary Account Number:
	  	[***]
		
	 Bank Name & Address:
	  	[***]

 “Company Group” means the Company and each of its Subsidiaries and Subsidiary Undertakings;

 “Confidential Information” means any and all technical and non-technical non-public information provided by either Party to the other (including, without limitation, the Royalty Reports, the Royalty Records and any notices or other information provided pursuant to

  
 4 

 
Clauses 4 and 5), either directly or indirectly, and including any materials prepared on the basis of such information, whether in graphic, written, electronic or oral form, and marked or
identified at the time of disclosure as confidential, or which by its context would reasonably be deemed to be confidential, including without limitation information relating to a Party’s technology, products and services, and any business,
financial or customer information relating to a Party. The existence and terms of this Agreement and the Placement Agent Agreement shall be deemed the Confidential Information of both Parties; 

“Contingent Obligation” means, for any Person, any direct or indirect liability, contingent or not, of that Person for any
indebtedness, lease, dividend, letter of credit or other obligation of another Person directly or indirectly guaranteed, endorsed, co-made, discounted or sold with recourse by that Person, or for which that
Person is directly or indirectly liable (other than by endorsements of instruments in the course of collection); 
 “Daily
VWAP” means, for any VWAP Trading Day, the per share volume-weighted average price of the Common Shares as displayed under the heading “Bloomberg VWAP” on Bloomberg page “LMDX <EQUITY> AQR” (or, if such page is not
available, its equivalent successor page) in respect of the period from the scheduled open of trading until the scheduled close of trading of the primary trading session on such VWAP Trading Day up to and including the final closing print (which is
indicated by “Condition Code 6” in Bloomberg) (or, if such volume-weighted average price is unavailable, the market value of one Common Share on such VWAP Trading Day, determined, using a volume-weighted average price method, by a
nationally recognized independent investment banking firm selected by the Company). The Daily VWAP will be determined without regard to after-hours trading or any other trading outside of the regular trading session; 

“Equity Interests” means, with respect to any Person, collectively, any and all shares, interests, participations or other
equivalents (however designated) of capital stock of a corporation, any and all equivalent ownership interests in such Person (other than a corporation), including partnership interests and membership interests, and any and all warrants, rights or
options to purchase or other arrangements or rights to acquire (by purchase, conversion, dividend, distribution or otherwise) any of the foregoing (and all other rights, powers, privileges, interests, claims and other property in any manner arising
therefrom or relating thereto); provided, however, that Indebtedness convertible into Equity Interests (or into any combination of cash and Equity Interests based on the value of such Equity Interests) shall not constitute Equity Interests unless
and until (and solely to the extent) so converted into Equity Interests; 
 “Excluded Jurisdictions” means any country other
than [***]; 
 “Expenses” has the meaning set out Clause 12.1; 

“Extended Initial Royalty Expiry Date” has the meaning set forth in Clause 3.5(a); 

“Extended Subsequent Royalty Expiry Date” has the meaning set forth in Clause 3.10(a); 

“Family Relative” means, with respect to any Person, such Person’s spouse, civil partner, parents, children,
step-children, siblings, mother-in-law, father-in-law, brothers and sisters-in-law, whether by blood, marriage or adoption; 

“Focus Fund I” has the meaning set forth in recital (2); 

“Focus Fund II” has the meaning set forth in recital (3); 

  
 5 

 “Indebtedness” means, with respect to any Person, without duplication:
(a) all indebtedness for advanced or borrowed money of, or credit extended to, such Person; (b) all obligations issued, undertaken or assumed by such Person as the deferred purchase price of assets, properties, services or rights;
(c) the face amount of all letters of credit issued for the account of such Person and, without duplication, all drafts drawn thereunder and all reimbursement or payment obligations with respect to letters of credit, surety bonds, performance
bonds and other similar instruments issued by such Person; (d) all obligations of such Person evidenced by notes, bonds, debentures or other debt securities or similar instruments (including debt securities convertible into Equity Interests),
including obligations so evidenced incurred in connection with the acquisition of properties, assets or businesses; (e) all indebtedness of such Person created or arising under any conditional sale or other title retention agreement or incurred
as financing, in either case with respect to property acquired by such Person (even though the rights and remedies of the seller or bank under such agreement in the event of default are limited to repossession or sale of such property); (f) any
obligations in respect of any Capital Lease of such Person; (g) the principal balance outstanding under any synthetic lease, off-balance sheet loan or similar off balance sheet financing product by such
Person; (h) all indebtedness referred to in clauses (a) through (g) above of other Persons secured by (or for which the holder of such indebtedness has an existing right, contingent or otherwise, to be secured by) any Lien upon or in
assets or properties (including accounts and contracts rights) owned by such Person, even though such Person has not assumed or become liable for the payment of such indebtedness of such other Persons; and (i) all Contingent Obligations of such
Person; 
 “Independent Accountant” has the meaning set forth in Clause 5.1; 

“Initial Closing” means the occurrence of the actions set out in Clause 6.2 on the Initial Closing Date; 

“Initial Closing Date” means the date of this Agreement (being 27 April 2022, or such other date as may be agreed by the
Company and the Investor Representative); 
 “Initial Invested Amount” has the meaning set forth in Clause 2.1(a); 

“Initial Market Share Price” means the simple average of the Daily VWAP for the twenty (20) VWAP Trading Days immediately
following the Initial Royalty Expiry Date; 
 “Initial New Instruments” means ten thousand four hundred and forty (10,440)
New Instruments, being the estimated number of New Instruments to be Allocated with the Initial Invested Amount for the purposes of this Agreement; 

“Initial Royalty Expiry Date” means the date that falls three (3) years after the Initial Closing Date; 

“Initial Royalty Payment” has the meaning set out forth in Clause 3.1 and “Initial Royalty Payments” shall be
construed accordingly 
 “Initial Royalty Shortfall” means the difference, in US Dollars, between the Initial Target
Return and the Total Initial Royalty Payments; 
 “Initial Share Price Difference” means an amount equal to the Minimum
Share Price minus the Initial Market Share Price; 
 “Initial Target Return” means an amount equal to two (2) times the
value of the Initial Invested Amount; 
 “Initial Threshold” has the meaning Clause 3.3; 

  
 6 

 “Initial True Up Notice” has the meaning Clause 3.3; 

“Initial True Up Share Price” means the higher of (a) the Initial Market Share Price; and (b) the Minimum Share
Price; 
 “Initial True Up Shares” means such number of Common Shares that is calculated by dividing the Initial Royalty
Shortfall by the Initial True Up Share Price; 
 “Invested Amount” has the meaning set forth in Clause 2.1; 

“Investor Parties” has the meaning given to that term in Clause 3.11; 

“Investor Representative” means PTP, for and on behalf of the Investors; 

“Investors’ Account” means such account(s) as designated by the Investor Representative to the Company in writing from
time to time; 
 “Laws” means, collectively, all international, foreign, federal, state and local statutes, treaties, rules,
guidelines, regulations, ordinances, codes and administrative or judicial precedents or authorities, including the interpretation or administration thereof by any governmental authority charged with the enforcement, interpretation or administration
thereof, and all applicable administrative orders, directed duties, requests, licenses, authorizations and permits of, and agreements with, any governmental authority, in each case, whether or not, having the force of law; 

“Lien” means a claim, mortgage, deed of trust, levy, charge, pledge, security interest or other encumbrance of any kind or
assignment for security purposes, whether voluntarily incurred or arising by operation of law or otherwise against any property or assets; 

“LumiraDx POC Platform” has the meaning set forth in recital (A); 

“Minimum Share Price” means a price per Common Share of $7.25; 

“Net Initial Strip Sales” means the total gross amount invoiced by the Company Group in respect of Sales or other dispositions
of Test Strips for usage in the Initial New Instruments by the Company Group (or any permitted assignee or transferee hereunder), less the Net Sale Deductions; 

“Net Sale Deductions” means the following deductions to the extent included in the gross amount invoiced in respect of
Sales or other dispositions of Test Strips: (a) rebates, credits or allowances actually granted for damaged or defective products, returns or rejections of such Test Strips or recalls, or for retroactive price reductions and billing errors;
(b) normal and customary trade, cash, quantity and other customary discounts, allowances and credits (including chargebacks) given to Third Parties in the ordinary course of business; (c) distribution services agreement fees and other
similar amounts allowed or paid to Third Party distributors, including specialty distributors of such Test Strips, (d) rebates made with respect to Sales paid for by any governmental authority, their agencies and purchasers and reimbursers,
managed health care organizations, or to trade customers; (e) the portion of administrative fees paid during the relevant time period to group purchasing organizations or pharmaceutical benefit managers relating to such Test Strips;
(f) any invoiced amounts that are not collected by the Company Group, including bad debts; and (g) any customary or similar payments to the foregoing (a) – (f) that apply to the Sale or disposition of analogous products; 

“Net Strip Sales” means any Net Initial Strip Sales or Net Subsequent Strip Sales; 

  
 7 

 “Net Subsequent Strip Sales” means the total gross amount invoiced in
respect of Sales or other dispositions of Test Strips for usage in the Subsequent New Instruments by the Company Group (or any permitted assignee or transferee hereunder), less the Net Sale Deductions; 

“New Instruments” means LumiraDx POC Platform testing instruments; 

“Okurowski Vehicle” has the meaning set out in recital (5); 

“Other Instruments” has the meaning set forth in Clause 4.1; 

“Person” means any natural person, firm, corporation, limited liability company, partnership, joint venture, association,
joint-stock company, trust, unincorporated organization, governmental authority or any other legal entity, including public bodies, whether acting in an individual, fiduciary or other capacity; 

“Placement Agent Agreement” means the Amended and Restated placement agent agreement entered into between USB and the Company
dated 7 April 2022; 
 “Pre-Contractual Statement” has the meaning set forth in
Clause 16.2(b); 
 “PTP” has the meaning set forth in recital (4); 

“Purpose” has the meaning set forth in Clause 8.1; 

“Recipient” has the meaning set forth in Clause 8.1; 

“Reporting Period” means the six month time period ending on a Semi-Annual End Date; 

“Royalty Records” has the meaning set forth in Clause 4.3; 

“Royalty Report” has the meaning set forth in Clause 4.2; 

“Royalty Payment Date” means the date that is forty five (45) days after each Semi-Annual End Date (provided if any such
date is not a Business Day, the Royalty Payment Date shall be the next following Business Day); 
 “Royalty Payments”
means the Initial Royalty Payments and any Subsequent Royalty Payments; 
 “Royalty Rate” means twenty percent (20%); 

“Sale” means, with regard to any New Instrument or Test Strip, any form of sale or reagent rental agreement, or any
contractual commitment to sell, or any award under a tender or grant of the right, or any other agreement, to sell, other than in an Excluded Jurisdiction; and “Sales” or “Sold” shall be construed accordingly; 

“SEC” means the Securities and Exchange Commission or any successor agency or authority thereto. 

“Securities Act” means the U.S. Securities Act of 1933, as amended; 

“Semi-Annual End Date” means each March 31, and September 30 of each year, commencing on the date agreed between the
Company and the Investor Representative (provided if any such date is not a Business Day, the Semi-Annual End Date shall be the next following Business Day); 

“Subsequent (1) New Instruments” has the meaning set forth in Clause 2.5; 

  
 8 

 “Subsequent (2) New Instruments” has the meaning
set forth in Clause 2.5; 
 “Subsequent Closing” means the occurrence of the actions set out in Clause 6.3 on each
Subsequent Closing Date; 
 “Subsequent Closing Date” is the date set out in each Subsequent Investment Notice; 

“Subsequent Closing Date (1)” has the meaning set forth in Clause 2.5; 

“Subsequent Closing Date (2)” has the meaning set forth in Clause 2.5; 

“Subsequent Invested Amount” has the meaning set out in Clause 2.1(b); 

“Subsequent Investment Notice” has the meaning set out in Clause 2.2; 

“Subsequent Market Share Price” means the simple average of the Daily VWAP for the twenty (20) VWAP Trading Days
immediately following the applicable Subsequent Royalty Expiry Date; 
 “Subsequent New Instruments” means the number of New
Instruments to be Allocated with any Subsequent Invested Amount for the purposes of this Agreement; 
 “Subsequent Royalty
Expiry Date” means the date that falls three (3) years after the relevant Subsequent Closing Date with respect to the funding of the relevant batch of Subsequent New Instruments; such that the “Subsequent Royalty Expiry
Date” for the Subsequent Royalty Payments relating to Subsequent (1) New Instruments shall be three (3) years after Subsequent Closing Date (1) and the Subsequent Royalty Expiry Date for Subsequent Royalty Payments relating
to the Subsequent (2) New Instruments shall be three (3) years after Subsequent Closing Date (2) and so on for each Subsequent Closing Date; 

“Subsequent Royalty Payment” has the meaning set forth in Clause 3.6(b); 

“Subsequent Royalty Shortfall” means in the event that the Subsequent Target Return is not achieved, the difference in US
Dollars between the Subsequent Target Return and the Total Subsequent Royalty Payments relating to such Subsequent Invested Amount; 

“Subsequent Share Price Difference” means an amount equal to the Minimum Share Price minus the Subsequent Market Share Price;

 “Subsequent Target Return” means an amount equal to two (2) times the value of the relevant Subsequent Invested
Amount; 
 “Subsequent Threshold” has the meaning set out in Clause 3.8; 

“Subsequent True Up Notice” has the meaning set out in Clause 3.8; 

“Subsequent True Up Share Price” means the higher of (a) the Subsequent Market Share Price; and (b) the Minimum
Share Price; 
 “Subsequent True Up Shares” means such number of Common Shares that is calculated by dividing the Subsequent
Royalty Shortfall by the Subsequent True Up Share Price; 
 “Subsidiary” and “Subsidiary Undertaking” shall
have the meaning ascribed to them in the Companies Act 2006; 
 “Tax” means all forms of taxation whether of the United
Kingdom, United States or elsewhere and whether direct or indirect and whether levied by reference to actual, deemed, gross or net income, profits, gains, net wealth, asset values, turnover, added value, receipt, payment, sale,

  
 9 

 
use, occupation, franchise or values or other reference and statutory, governmental, state, provincial, local governmental or municipal impositions, duties, contributions, rates and levies
(including without limitation social security contributions and any other payroll taxes), whenever and wherever imposed (whether imposed by way of a withholding or deduction for or on account of tax or otherwise) and in respect of any person and all
related penalties, charges, surcharges, fines and interest relating thereto; 
 “Test Strips” means the LumiraDx
microfluidic test strips designed for use in the LumiraDx POC Platform; 
 “Third Party” means any Person other than
(a) the Company, (b) the Investors or (c) an Affiliate of either the Company or the Investors (as applicable); 

“Total Initial Royalty Payments” means, by the Initial Royalty Expiry Date, the total amount of Initial Royalty Payments paid
by the Company to the Investors under the terms of this Agreement; 
 “Total Invested Amount” has the meaning set out in
Clause 2.1(b); 
 “Total Subsequent Royalty Payments” means, by the relevant Subsequent Royalty Expiry Date, the total
amount of relevant Subsequent Royalty Payments paid by the Company to the Investors under the terms of this Agreement; 
 “True Up
Shares” means the Initial True Up Shares and any Subsequent True Up Shares; 
 “United Kingdom” means the United
Kingdom of Great Britain and Northern Ireland; 
 “Umphrey Vehicle” has the meaning set out in recital (4); 

“U.S.” or “United States” means the United States of America, its 50 states, each territory and possession
thereof and the District of Columbia; 
 “USB” means U.S. Boston Capital Corporation; 

“VWAP Market Disruption Event” means, with respect to any date, (A) the failure by the principal U.S. national or
regional securities exchange on which the Common Shares are then listed, or, if the Common Shares are not then listed on a U.S. national or regional securities exchange, the principal other market on which the Common Shares are then traded, to open
for trading during its regular trading session on such date; or (B) the occurrence or existence, for more than one half hour period in the aggregate during the regular trading session, of any suspension or limitation imposed on trading (by
reason of movements in price exceeding limits permitted by the relevant exchange or otherwise) in the Common Shares or in any options contracts or futures contracts relating to the Common Shares, and such suspension or limitation occurs or exists at
any time before 1:00 p.m., New York City time, on such date; and 
 “VWAP Trading Day” means a day on which (A) there
is no VWAP Market Disruption Event; and (B) trading in the Common Shares generally occurs on the principal U.S. national or regional securities exchange on which the Common Shares are then listed or, if the Common Shares are not then listed on
a U.S. national or regional securities exchange, on the principal other market on which the Common Shares are then traded. If the Common Shares are not so listed or traded, then “VWAP Trading Day” means a Business Day. 

 

	1.2	 References to “Clauses” are to the clauses of this Agreement. 

 

	1.3	 References to the “Schedules” are to the schedules to this Agreement, which form part of this
Agreement and have the same force and effect as if set out in the body of this Agreement. 

  
 10 

	1.4	 Where any capitalised term is defined within a particular Clause in the body of this Agreement or in a
Schedule, that term shall bear the meaning ascribed to it in that Clause or Schedule wherever it is used in this Agreement. 

Interpretation 
  

	1.5	 The table of contents and headings to Clauses and Schedules and are included for ease of reference only, and
are not to affect the interpretation of this Agreement. 

  

	1.6	 In this Agreement, unless expressly stated otherwise: 

 

	 	(a)	 the words “include” or “including” (or any similar term) are not to be
construed as implying any limitation; 

  

	 	(b)	 general words shall not be given a restrictive meaning by reason of the fact that they are preceded or followed
by words indicating a particular class of acts, matters or things; 

  

	 	(c)	 words indicating gender shall be treated as referring to the masculine, feminine or neuter as appropriate;

  

	 	(d)	 a reference to a statute, statutory provision or subordinate legislation (“legislation”)
refers to such legislation as it is in force at the date of this Agreement; 

  

	 	(e)	 any reference to any document other than this Agreement is a reference to that other document as amended,
varied, supplemented, or novated (in each case, other than in breach of the provisions of this Agreement) at any time; 

  

	 	(f)	 references to the time of day are to London time unless otherwise specified; 

 

	 	(g)	 a reference to something being “in writing” or “written” includes any mode of
representing or reproducing words in visible form that is capable of reproduction in hard copy form, including words transmitted by fax or email but excluding any other form of electronic or digital communication; 

 

	 	(h)	 any reference to a “holding company” or a “subsidiary” means a
“holding company” or “subsidiary” as defined in section 1159 of the Companies Act 2006, save that a company shall be treated for the purposes of the membership requirement contained in sections 1159(1)(b) and
(c) as a member of another company even if its shares in that other company are registered in the name of (i) its nominee or (ii) another person (or its nominee) by way of security or in connection with the taking of security. Any
reference to an “undertaking” shall be construed in accordance with section 1169 of the Companies Act 2006 and any reference to a “parent company” or a “subsidiary undertaking” means
respectively a “parent company” or “subsidiary undertaking” as defined in sections 1162 and 1173(1) of the Companies Act 2006, save that an undertaking shall be treated for the purposes of the membership
requirement in sections 1162(2)(b) and (d) and section 1162(3)(a) as a member of another undertaking even if its shares in that other undertaking are registered in the name of (i) its nominee or (ii) another person (or its nominee) by
way of security or in connection with the taking of security; 

  

	 	(i)	 a person shall be deemed to be connected with another if that person is connected with another within the
meaning of section 1122 of the Corporation Tax Act 2010; and 

  

	 	(j)	 any reference to any English legal term for any action, remedy, method of judicial proceeding, legal document,
legal status, court, official or any legal concept or thing shall, in respect of any jurisdiction other than England, be deemed to include what most nearly approximates in that jurisdiction to the English legal term. 

  
 11 

	2.	 PAYMENT OF THE INVESTED AMOUNT 

 

	2.1	 On and subject to the terms of this Agreement, the Investors shall pay (or cause to be paid) to the Company, or
the Company’s designee, the following: 

  

	 	(a)	 on the Initial Closing Date, twenty six million and one hundred thousand US Dollars ($26,100,000), in
aggregate, (the “Initial Invested Amount”), in immediately available funds by wire transfer to the Company Account. Each Investor shall contribute the amount of the Initial Invested Amount set out in column (A) of Schedule 1 of
this Agreement; and 

  

	 	(b)	 on any Subsequent Closing Date, subject to the satisfaction of the conditions set forth in Clauses 2.2 and 2.4,
such further amounts (each a “Subsequent Invested Amount”), being in minimum tranches of ten million US Dollars ($10,000,000) (or such lower minimum amount as agreed to by the Company and the Investor Representative), up to a
maximum amount (which shall include, for the avoidance of doubt, the Initial Invested Amount) of fifty million US Dollars ($50,000,000) or such higher amount as agreed to by the Company and the Investor Representative (the “Total Invested
Amount”), in immediately available funds by wire transfer to the Company Account. 

 For the purposes of
this Agreement, the term “Invested Amount” shall be deemed to include all amounts paid by the Investors to the Company from time to time under this Agreement and shall include the Initial Invested Amount paid to the Company on the
Initial Closing Date and any Subsequent Invested Amounts paid to the Company on a Subsequent Closing Date. 
  

	2.2	 In advance of the Investors paying a Subsequent Invested Amount to the Company on a Subsequent Closing Date,
the Investor Representative (for and on behalf of the Investors) shall serve a notice (a “Subsequent Investment Notice”) on the Company at least seven (7) Business Days prior to the proposed Subsequent Closing Date (or on such
shorter notice period as agreed to between the Company and the Investor Representative). If the proposed Subsequent Closing Date is on or prior to 30 June 2022 (or such other date as may be agreed by the Company and the Investor
Representative), then the Company shall be obliged to accept the Subsequent Invested Amount. 

  

	2.3	 If, however, the Subsequent Closing Date is on or after 1 July 2022, the Company shall within three
(3) Business Days of its receipt of the Subsequent Investment Notice confirm in writing to the Investor Representative that it either: 

  

	 	(a)	 accepts the Subsequent Invested Amount and accordingly the Parties shall proceed to a Subsequent Closing on the
proposed Subsequent Closing Date; or 

  

	 	(b)	 does not accept the Subsequent Invested Amount and accordingly the Parties shall not proceed to a Subsequent
Closing on the proposed Subsequent Closing Date. The Company shall be deemed to have not accepted the Subsequent Invested Amount if it fails to respond to a Subsequent Investment Notice within the three (3) Business Day period.

  

	2.4	 The Subsequent Investment Notice: 

 

	 	(a)	 must specify the proposed Subsequent Closing Date (which shall be a date that falls no earlier than seven
(7) Business Days after the date of the Subsequent Investment Notice or such other date as agreed to between the Company and the Investor Representative); 

 

	 	(b)	 must specify the amount of the Subsequent Invested Amount to be paid by each of the Investors to the Company on
the proposed Subsequent Closing Date and accordingly the proportion of the Subsequent Royalty Payment that each Focus Fund is entitled to. Each Subsequent Invested Amount must be at least ten million US Dollars ($10,000,000) (unless the Company and
the Investor Representative agree to a lower amount); 

  
 12 

	 	(c)	 shall be signed by an authorised representative of the Investor Representative; 

 

	 	(d)	 shall not be capable of being withdrawn once given by the Investor Representative; and 

 

	 	(e)	 shall be in the form set out in Schedule 2 to this Agreement. 

 

	2.5	 The Company shall confirm to the Investor Representative in writing the number of Subsequent New Instruments to
be Allocated with each Subsequent Invested Amount on or prior to the relevant Subsequent Closing Date. The batch of Subsequent New Instruments Allocated following the first Subsequent Closing Date (“Subsequent Closing Date (1)”)
shall be referred to as the “Subsequent (1) New Instruments” and the batch of Subsequent New Instruments Allocated following the second Subsequent Closing Date (“Subsequent Closing Date (2)”)
shall be referred to as the “Subsequent (2) New Instruments” and so on for each Subsequent Closing. 

  

	2.6	 The Parties agree that each batch of New Instruments Allocated in accordance with this Agreement shall be
separately categorized and recorded by the Company for the purposes of the calculation and payment of the relevant Royalty Payment pursuant to Clause 3 below. Such categorization shall be the sole responsibility of the Company. The New Instruments
Allocated with the Initial Invested Amount are referred to herein as the Initial New Instruments and the New Instruments Allocated with each Subsequent Invested Amount are referred to herein as the Subsequent New Instruments. For purposes of this
Agreement, a LumiraDx POC Platform testing instrument is “Allocated” with a particular Invested Amount if it is Sold during the period commencing upon the Initial Closing or Subsequent Closing (as applicable) to such Invested Amount and
ending when the number of LumiraDx POC Platform testing instruments Sold equals (i) such Invested Amount divided by (ii) two thousand five hundred U.S. dollars ($2,500). 

 

	3.	 ROYALTY PAYMENT 

Initial Royalty Payment 
  

	3.1	 In consideration of the Investors paying the Initial Invested Amount to the Company in accordance with Clause
2.1(a) above, the Parties agree that until the Initial Royalty Expiry Date or, to the extent Clause 3.5(a) applies, the Extended Initial Royalty Expiry Date, the Company shall pay to the Investors on each Royalty Payment Date an amount equal, in
aggregate, to the product of: 

  

	 	(a)	 the Royalty Rate; and 

 

	 	(b)	 the Net Initial Strip Sales for the relevant Reporting Period, 

(the “Initial Royalty Payment”). Each Investor shall be entitled to such proportion of the Initial Royalty Payment as
is set out in column (B) of Schedule 1 of this Agreement. 
  

	3.2	 Each Initial Royalty Payment shall be paid by the Company to the Investors in immediately available funds by
wire transfer to the Investors’ Account and receipt of the amount due into the relevant account shall constitute an effective discharge of the relevant payment obligation. 

 

	3.3	 If by the Initial Royalty Expiry Date the Investors have not received, in aggregate, Initial Royalty Payments
equal to or in excess of the Initial Target Return (the “Initial Threshold”), the Company shall send a notice (“Initial True Up Notice”) to the Investors within forty (40) days of the Initial Royalty Expiry
Date confirming that: 

  

	 	(a)	 the Initial Threshold has not been achieved; 

  
 13 

	 	(b)	 the Company shall either: 

 

	 	(i)	 issue the Initial True Up Shares pursuant to Clause 3.4(a) below; or 

 

	 	(ii)	 pay the Initial Royalty Shortfall in cash pursuant to Clause 3.4(b) below; and 

 

	 	(c)	 to the extent the Company elects to issue the Initial True Up Shares: 

 

	 	(i)	 the number of Initial True Up Shares that each Investor is entitled to; and 

 

	 	(ii)	 the issue price of the Initial True Up Shares and whether such Initial True Up Shares shall be issued at the
Initial Market Share Price or the Minimum Share Price (whichever is higher) or if they are the same, at the Initial Market Share Price, 

and the Parties hereby agree that the decision to proceed on the basis of Clause 3.3(b)(i) or Clause 3.3(b)(ii) shall be made by the Company in
its sole discretion. 
  

	3.4	 As soon as reasonably practicable following the date of the Initial True Up Notice, the Company shall:

  

	 	(a)	 to the extent the Company has elected to issue the Initial True Up Shares pursuant to Clause 3.3(b)(i) above,
allot and issue, credited as fully paid, the Initial True Up Shares to the Investors in the proportions set out in the column (C) of Schedule 1 of this Agreement. Any Initial True Up Shares issued to the Investors shall rank equally in all
respects with the other then existing Common Shares on and from the date of allotment and such Initial True Up Shares shall be entitled to all dividends and other distributions attaching to the Common Shares which are declared and payable after the
date of allotment of such Initial True Up Shares and the Initial True Up Shares shall be subject to the rights and obligations set forth in the Articles of Association; or 

 

	 	(b)	 to the extent the Company has elected to settle the Initial Royalty Shortfall in cash pursuant to Clause
3.3(b)(ii) above, pay an amount equal to the Initial Royalty Shortfall in cash to the Investors in the proportions set out in the column (C) of Schedule 1 of this Agreement. 

 

	3.5	 The Parties agree and acknowledge that to the extent: 

 

	 	(a)	 the Initial True Up Shares are issued at the Minimum Share Price, the Parties agree that the period that the
Company is required to pay the Initial Royalty Payments to the Investors under Clause 3.1 shall be extended until such date that the Investors receive, in aggregate, an amount equal to the Additional Royalty Shortfall (the “Extended Initial
Royalty Expiry Date”). Once the Investors receive Initial Royalty Payments up to an amount equal, in aggregate, to the Additional Royalty Shortfall, the Company shall then have no further obligation to pay the Initial Royalty Payment and
the Investors will not be entitled to any additional payments with respect to the Initial New Instruments; or 

  

	 	(b)	 the Initial True Up Shares are issued at the Initial Market Share Price or the Initial Threshold is achieved or
the Initial Royalty Shortfall is paid in cash in accordance with Clause 3.4(b), the Company shall have no further obligation to pay the Initial Royalty Payment and the Investors will not be entitled to any additional payments with respect to the
Initial New Instruments. 

 Subsequent Royalty Payment 

 

	3.6	 In consideration of the Investors paying a Subsequent Invested Amount to the Company in accordance with Clause
2.1(b) above, the Parties agree that until the applicable Subsequent 

  
 14 

	 	
Royalty Expiry Date or, to the extent Clause 3.10(a) applies, the applicable Extended Subsequent Royalty Expiry Date, the Company shall pay to the Investors on each Royalty Payment Date an amount
equal, in aggregate, to the product of: 

  

	 	(a)	 the Royalty Rate; and 

 

	 	(b)	 the Net Subsequent Strip Sales for the relevant Reporting Period (the “Subsequent Royalty
Payment”), 

 separately calculated for each batch of Subsequent New Instruments (i.e. a Subsequent Royalty
Payment will be payable in respect of Subsequent (1) New Instruments and a separate Subsequent Royalty Payment shall be payable in respect of Subsequent (2) New Instruments and so on).  

 

	3.7	 Each Subsequent Royalty Payment shall be paid by the Company to the Investors in immediately available funds by
wire transfer to the Investors’ Account and receipt of the amount due into the relevant account shall constitute an effective discharge of the relevant payment obligation. 

 

	3.8	 If by the applicable Subsequent Royalty Expiry Date the Investors have not received, in aggregate, Subsequent
Royalty Payments equal to or in excess of the Subsequent Target Return for that particular batch of Subsequent New Instruments (the “Subsequent Threshold”) the Company shall send a notice (the “Subsequent True Up
Notice”) to the Investors within forty (40) days of the applicable Subsequent Royalty Expiry Date confirming that: 

  

	 	(a)	 the Subsequent Threshold has not been achieved; 

 

	 	(b)	 the Company shall either: 

 

	 	(i)	 issue the Subsequent True Up Shares pursuant to Clause 3.9(a) below; or 

 

	 	(ii)	 pay the applicable Subsequent Royalty Shortfall in cash pursuant to Clause 3.9(b) below; and

  

	 	(c)	 to the extent the Company elects to issue the Subsequent True Up Shares: 

 

	 	(i)	 the number of the Subsequent True Up Shares that each Investor is entitled to; and 

 

	 	(ii)	 the issue price of the Subsequent True Up Shares and whether such Subsequent True Up Shares will be issued at
the Subsequent Market Share Price or the Minimum Share Price (whichever is higher) or if they are the same, at the Subsequent Market Share Price, 

and the Parties hereby agree that the decision to proceed on the basis of Clause 3.8(b)(i) or Clause 3.8(b)(ii) shall be made by the Company in
its sole discretion. 
  

	3.9	 As soon as reasonably practicable following the date of the Subsequent True Up Notice, the Company shall:

  

	 	(a)	 to the extent the Company has elected to issue the Subsequent True Up Shares pursuant to Clause 3.8(b)(i)
above, allot and issue, credited as fully paid, the Subsequent True Up Shares to the Investors pro rata to the amount of the Subsequent Invested Amount paid by each of the Investors. Any Subsequent True Up Shares issued to the Investors shall rank
equally in all respects with the other then existing Common Shares on and from the date of allotment and such Subsequent True Up Shares shall 

  
 15 

	 	
be entitled to all dividends and other distributions attaching to the Common Shares which are declared and payable after the date of allotment of such Subsequent True Up Shares and the Subsequent
True Up Shares shall be subject to the rights and obligations set forth in the Articles of Association; or 

  

	 	(b)	 to extent the Company has elected to settle the applicable Subsequent Royalty Shortfall in cash pursuant to
Clause 3.8(b)(ii) above, pay an amount equal to the applicable Subsequent Royalty Shortfall in cash to the Investors in the proportions set out in the column (C) of the relevant Subsequent Investment Notice. 

 

	3.10	 The Parties agree and acknowledge that to the extent: 

 

	 	(a)	 the Subsequent True Up Shares are issued at the Minimum Share Price, the Parties agree that the period that the
Company is required to pay the applicable Subsequent Royalty Payments to the Investors under Clause 3.6 of this Agreement shall be extended until such date that the Investors receive, in aggregate, an amount equal to the Additional Royalty Shortfall
(the “Extended Subsequent Royalty Expiry Date”). Once the Investors receive Subsequent Royalty Payments up to an amount equal to, in aggregate, the Additional Royalty Shortfall, the Company shall then have no further obligation to
pay the applicable Subsequent Royalty Payment and the Investors will not be entitled to any additional payments with respect to such Subsequent New Instruments; or 

 

	 	(b)	 the Subsequent True Up Shares are issued at the Subsequent Market Share Price or the Subsequent Threshold is
achieved or the applicable Subsequent Royalty Shortfall is paid in cash in accordance with Clause 3.9(b), the Company shall have no further obligation to pay the applicable Subsequent Royalty Payment and the Investors will not be entitled to any
additional payments with respect to that particular batch of Subsequent Test Instruments. 

 Not Indebtedness;
Unsecured; No Partnership; No Transfer 
  

	3.11	 The Parties hereby confirm and agree that notwithstanding the terms of this Agreement the obligations under
this Agreement including but not limited to the obligation to pay the Royalty Payments and the obligation to issue any True Up Shares are and will be unsecured and shall not in any circumstances constitute Indebtedness of the Company. The Parties
hereby confirm and agree that notwithstanding the terms of this Agreement, the Investors, the Investor Representative, each of their respective Affiliates and, to the extent applicable, each of the investors in the Investors (collectively the
“Investor Parties”) shall have no recourse to the New Test Instruments, any Test Strips or any other asset of the Company Group and the arrangements contemplated herein shall not constitute a Lien on, or sale, transfer or other
disposal of, the New Instruments, the Test Strips or any other asset of the Company Group in favour of or to any of the Investor Parties. Furthermore without prejudice to the generality of the foregoing, the Parties hereby confirm and agree that
notwithstanding the terms of this Agreement, the Investor Parties shall not, by virtue of funding the Invested Amount or by virtue of any other provision set out in this Agreement or in any other contract, arrangement or agreement between the
Parties, purchase, acquire or accept any of the New Instruments, including assets or contractual rights of the Company Group related thereto, or any other assets or contractual rights of the Company Group, other than its rights with respect to the
Royalty Payments and rights to receive the True Up Shares. In addition, the Parties hereby confirm and agree that this Agreement shall not be interpreted or construed to create an association, joint venture, agency relationship, or
partnership among the Parties for any purpose (including for tax purposes) or to impose any partnership obligation or partnership liability upon any Party. The Investors and the Investor
Representative hereby undertake that they shall not (and undertake to ensure that the other Investor Parties shall not) challenge, or support any other Person in challenging, the confirmations and agreements set out in this Clause 3.11 or otherwise
take or cause to be taken any action the purpose or intent of which is, or could be, to contradict, in any manner, the terms of this Clause 3.11. 

  
 16 

 General 
  

	3.12	 No Royalty Payment shall accrue interest and no Royalty Payment shall be paid until the applicable Royalty
Payment Date. 

  

	3.13	 On any Royalty Payment Date, the Company shall have the right to, at its option, fund all of the Royalty
Payments that are due and payable in one (1) aggregate payment to the relevant Investor (including the Initial Royalty Payment and any Subsequent Royalty Payment that is due and payable) and such payment by the Company shall be in full and
final discharge of the relevant payment obligations. 

  

	3.14	 All payments made by a Party hereunder shall be made by deposit of U.S. Dollars by wire transfer in immediately
available funds into the applicable account. 

  

	3.15	 The rate of exchange for any Net Strip Sales denominated in a currency other than US Dollars shall be the
exchange rate at which the Company converted such currency into US Dollars. 

  

	4.	 REPORTS 

Tracking 
  

	4.1	 Following the payment of any Invested Amount, the Company shall separately track, record and log:

  

	 	(a)	 the Sale by the Company Group of the New Instruments as opposed to all other LumiraDx POC Platform testing
instruments of the Company Group which are not Allocated pursuant to the terms of this Agreement (the “Other Instruments”) and, for the avoidance of doubt, the term Other Instruments shall include any LumiraDx POC Platform testing
instruments manufactured and/or allocated in connection with any arrangement entered into by a member of the Company Group with the Bill and Melinda Gates Foundation; 

 

	 	(b)	 the Net Strip Sales as opposed to the Sale by the Company Group of all other Test Strips for usage in the Other
Instruments; 

  

	 	(c)	 the Sale of: (i) the Initial New Instruments; and (ii) each batch of Subsequent New Instruments; and

  

	 	(d)	 the: (i) Net Initial Strip Sales; and (ii) each applicable Net Subsequent Strip Sales.

 Reports and Records Retention 
  

	4.2	 On each Royalty Payment Date, the Company shall deliver to the Investor Representative a written report (the
“Royalty Report”) setting out: 

  

	 	(a)	 the amount of Net Initial Strip Sales during the applicable Reporting Period; 

 

	 	(b)	 the amount of Net Subsequent Strip Sales during the applicable Reporting Period for each applicable batch of
Subsequent New Instruments; 

  

	 	(c)	 an itemized calculation of the amount of the Royalty Payments due in respect of the applicable Reporting
Period, showing on a standalone basis the amount of the Initial Royalty Payment and each Subsequent Royalty Payment; 

  

	 	(d)	 the aggregate Initial Royalty Payments paid up to the date of the Royalty Report; and 

  
 17 

	 	(e)	 the aggregate Subsequent Royalty Payments paid up to the date of the Royalty Report. 

 

	4.3	 The Company shall keep (and shall ensure that each member of the Company Group shall keep) complete, true and
accurate books of account and records showing the derivation of all amounts payable to the Investors in connection with this Agreement (the “Royalty Records”). The Royalty Records shall be preserved for a period of not less than 18
months after the final Royalty Payment is paid to the Investors under this Agreement. 

  

	4.4	 The Company will permit the Investor Representative, upon the Investor Representative providing reasonable
prior written notice, to inspect (at a reasonable time and location) the Royalty Records for the sole purpose of confirming whether the Royalty Payments paid to the Investors are correct. 

 

	4.5	 The Investor Representative shall be entitled to a semi-annual update call to discuss (i) the Royalty
Report, (ii) the contents of the Royalty Records; (iii) the progress of sales and product marketing efforts made by the Company in relation to the New Instruments; or (iv) such other matters that the Investor Representative in good
faith deems appropriate. 

  

	5.	 AUDIT 

  

	5.1	 Upon the written request of the Investor Representative, and not more than once in each calendar year, the
Company shall permit an independent certified public accounting firm of national prominence selected by the Investor Representative, and reasonably acceptable to the Company (the “Independent Accountant”), to have access to and to
review, during normal business hours and upon not less than sixty (60) days’ prior written notice, the Royalty Records as may reasonably be necessary to verify the accuracy and timeliness of the reports and payments (including calculation
and payment of any Royalty Payment) made by the Company under this Agreement, provided that no such audit shall be conducted in the calendar months of January, February, April, July or October. The Independent Accountant shall be permitted to
prepare and disclose to the Investor Representative a written report stating only whether the Royalty Payments paid to the Investors hereunder and the reports provided by the Company relating to such Royalty Payments required hereunder are correct
or incorrect and the specific details concerning any discrepancies. Subject to Clause 5.2 below, the fees and expenses of the Independent Accountant shall be borne entirely by the Investors. 

 

	5.2	 If the Independent Accountant reasonably concludes that any Royalty Payments were owed and were not paid when
due during such period pursuant to the provisions of this Agreement, the Company shall pay any late or unpaid Royalty Payments within sixty (60) days after the date the Investor Representative delivers to the Company a notice including the
Independent Accountant’s written report and requesting such payment. If the amount of the underpayment is greater than the lesser of (i) ten percent (10%) of the total amount actually owed for the period audited or (ii) one million
dollars ($1,000,000), then the Company shall in addition reimburse the Investor Representative for all reasonable costs and fees of the Independent Accountant related to such audit. In the event of overpayment, any amount of such overpayment shall
be creditable against the Royalty Payments payable for the immediately succeeding Reporting Period. 

  

	5.3	 The Investor Representative and each Investor shall: 

 

	 	(a)	 treat all information that it receives under this Clause 5 in accordance with the provisions of Clause 8; and

  

	 	(b)	 cause the Independent Accountant to enter into a reasonably acceptable confidentiality agreement with the
Company obligating such firm to retain all such information in confidence pursuant to such confidentiality agreement, in each case except to the extent necessary for the Investor Representative to enforce its rights under this Agreement.

  
 18 

	5.4	 All rights to an audit under this Clause 5 shall terminate one (1) year after the final Royalty Payment is
paid to the Investors under this Agreement. 

  

	6.	 CLOSING 

  

	6.1	 The Initial Closing and any Subsequent Closing shall take place electronically by the electronic exchange of
deliverables and release of signatures for the purpose of confirming the satisfaction or waiver, as the case may be, of any conditions set forth herein. 

  

	6.2	 At the Initial Closing: 

 

	 	(a)	 the Company shall: 

  

	 	(i)	 deliver or cause to be delivered to the Investor Representative the following: 

 

	 	(A)	 a counterpart of this Agreement signed by the Company; 

 

	 	(B)	 a copy of the minutes of a duly held meeting of the directors of the Company authorising the execution of this
Agreement and each of the other documents to which it is required to enter into pursuant to this Agreement; and 

  

	 	(C)	 confirmation of how many New Instruments it is estimated will be Allocated from the proceeds of the Initial
Invested Amount. 

  

	 	(b)	 the Investor Representative (for and on behalf of each Investor) shall: 

 

	 	(i)	 deliver or cause to be delivered to the Company a counterpart of this Agreement signed by each of the
Investors; and 

  

	 	(ii)	 pay, or cause to be paid, the Initial Invested Amount to the Company Account in accordance with Clause 2.1(a).

  

	6.3	 At each Subsequent Closing: 

 

	 	(a)	 the Company shall: 

  

	 	(i)	 deliver or cause to be delivered to the Investor Representative: 

 

	 	(A)	 confirmation of how many New Instruments it is estimated will be Allocated from the proceeds of the respective
Subsequent Invested Amount; and 

  

	 	(B)	 such other deliverables as agreed between the Parties for each respective Subsequent Closing.

  

	 	(b)	 the Investor Representative (for and on behalf of each Focus Fund) shall: 

 

	 	(i)	 pay the respective Subsequent Invested Amount to the Company Account; and 

 

	 	(ii)	 deliver or cause to be delivered to the Company such other deliverables as agreed between the Parties for each
respective Subsequent Closing. 

  
 19 

	7.	 WARRANTIES  

 

	7.1	 The Company warrants to each of the Investors that as at the Initial Closing Date, on each Subsequent Closing
Date and on any date that an Investor is issued True Up Shares that: 

  

	 	(a)	 It is duly incorporated and validly existing under the laws of the Cayman Islands; 

 

	 	(b)	 This Agreement and any other document to be executed by the Company in connection with this Agreement will,
when executed, constitute legal, valid and binding obligations of the Company enforceable in accordance with their respective terms; 

  

	 	(c)	 The execution and delivery of, and the performance of obligations under and compliance with, the provisions of
this Agreement by the Company will not result in violation of any provision of the Articles of Association or any other constitutional document of the Company; 

 

	 	(d)	 No order has been made, petition presented or meeting convened for the purpose of considering a resolution for
the winding up of the Company or for the appointment of any provisional liquidator. No petition has been presented for an administration order to be made in relation to the Company, and no receiver (including any administrative receiver) has been
appointed in respect of the whole or any part of any of the property, assets and/or undertaking of the Company; and 

  

	 	(e)	 The Company has filed all registration statements, forms, reports and other documents required to be filed by
the Company with the SEC since January 1, 2021, all of which are publicly available on the SEC’s EDGAR system. All such registration statements, forms, reports and other documents are referred to herein as the “Company SEC
Reports”. The Company SEC Reports (i) at the time filed, were prepared in compliance in all material respects with the applicable requirements of the Securities Act and the Exchange Act, as the case may be, and the rules and
regulations of the SEC thereunder applicable to such Company SEC Reports, and (ii) did not contain any untrue statement of a material fact or omit to state a material fact required to be stated in such Company SEC Reports or necessary in order
to make the statements in such Company SEC Reports, in the light of the circumstances under which they were made, not materially misleading; and 

  

	 	(f)	 Each of the consolidated financial statements (including, in each case, any related notes and schedules)
contained in the Company SEC Reports at the time filed (i) complied as to form in all material respects with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto, and (ii) fairly
presented the consolidated financial position of the Company and its subsidiaries as of the dates thereof and the consolidated results of its operations and cash flows for the periods indicated, consistent with the books and records of the Company
and its subsidiaries. Any unaudited interim financial statements were prepared on a basis consistent with the preparation of previous unaudited interim financial statements. 

 

	7.2	 Each of the Investors severally warrants to the Company that as at the Initial Closing Date, on each Subsequent
Closing Date and on any date that an Investor is issued True Up Shares that: 

  

	 	(a)	 To the extent the Investor is a firm, corporation, limited liability company, partnership or any other legal
entity (“Entity”), it is duly incorporated and validly existing under the laws of the jurisdiction in which such Investor was incorporated, as well as duly qualified to conduct the business to be conducted at the Initial Closing
Date, on each Subsequent Closing Date or on such date such Investor is issued True Up Shares (as applicable) and it has the requisite power and authority to enter into and perform this Agreement; 

 

	 	(b)	 Such Investor has the necessary funds to enter into and perform the obligations under this Agreement;

  

	 	(c)	 This Agreement and any other document to be executed by it in connection with this Agreement will, when
executed, constitute legal, valid and binding obligations of such Investor enforceable in accordance with their respective terms; 

  
 20 

	 	(d)	 The execution and delivery of, and the performance of obligations under and compliance with, the provisions of
this Agreement by such Investor will not result in: 

  

	 	(i)	 to the extent the Investor is an Entity, a violation of any provision of the constitutional documents of such
Investor; or 

  

	 	(ii)	 a breach of or a default under any agreement, arrangement or instrument to which such Investor is a party;

  

	 	(e)	 No consent, authorisation, licence or approval of or notice to, where applicable, such Investor’s members
or any governmental, administrative, judicial, regulatory body, authority or organisation is required to authorise the execution, delivery, validity, enforceability or admissibility in evidence of this Agreement or the performance by such Investor
of its obligations under this Agreement; 

  

	 	(f)	 To the extent the Investor: 

 

	 	(i)	 is an Entity, no order has been made, petition presented or meeting convened for the purpose of considering a
resolution for the winding up of such Investor or for the appointment of any provisional liquidator. No petition has been presented for an administration order to be made in relation to such Investor, and no receiver (including any administrative
receiver) has been appointed in respect of the whole or any part of any of the property, assets and/or undertaking of such Investor; or 

  

	 	(ii)	 is an individual, such Investor has not been declared bankrupt or had a bankruptcy petition presented against
him or been subject to any event analogous to the foregoing in any jurisdiction. 

  

	7.3	 Each Investor further warrants (on a several basis) that on any date that an Investor is issued True Up Shares
such Investor and, to the extent applicable, any underlying unitholder of such Investor is an “accredited investor” as defined in Rule 501(a) of Regulation D under the Securities Act and/or a “qualified institutional buyer” as
defined in Rule 144A under the Securities Act and/or a “qualified purchaser” within the meaning of Section 2(a)(51) under the Investment Company Act of 1940. 

 

	8.	 CONFIDENTIALITY 

 

	8.1	 During the term of this Agreement and for a period of three (3) years thereafter, each Party shall
maintain in strict confidence all Confidential Information and materials disclosed or provided to it by the other Party, except as approved in writing in advance by the disclosing Party, and shall not use or reproduce the disclosing Party’s
Confidential Information for any purpose other than as required to carry out its obligations and exercise its rights pursuant to this Agreement (the “Purpose”). The Party receiving such Confidential Information (the
“Recipient”) agrees to institute measures to protect the Confidential Information in a manner consistent with the measures it uses to protect its own most sensitive proprietary and confidential information, which must not be less
than a reasonable standard of care. Notwithstanding the foregoing, the Recipient may permit access to the disclosing Party’s Confidential Information to those of its employees or authorized representatives having a need to know such information
for the Purpose and who have signed confidentiality agreements or are otherwise bound by confidentiality obligations at least as restrictive as those contained herein. Each Party shall be responsible for the breach of this Agreement by its employees
or authorized representatives. Each Party shall immediately notify the other Party upon discovery of any loss or unauthorized disclosure of the other Party’s Confidential Information. 

  
 21 

 Exceptions 
  

	8.2	 The obligations of confidentiality and non-use set forth in Clause 8.1
shall not apply to any portion of Confidential Information that: 

  

	 	(a)	 the Recipient or its Affiliates can demonstrate was: 

 

	 	(i)	 known to the general public at the time of its disclosure to the Recipient or its Affiliates, or thereafter
became generally known to the general public, other than as a result of actions or omissions of the Recipient, its Affiliates, or anyone to whom the Recipient or its Affiliates disclosed such Confidential Information of the disclosing Party;

  

	 	(ii)	 known by the Recipient or its Affiliates prior to the date of disclosure by the disclosing Party;

  

	 	(iii)	 disclosed to the Recipient or its Affiliates on an unrestricted basis from a source unrelated to the disclosing
Party and not known by the Recipient or its Affiliates to be under a duty of confidentiality to the disclosing Party; or 

  

	 	(iv)	 independently developed by the Recipient or its Affiliates by personnel that did not use the Confidential
Information of the disclosing Party in connection with such development; or 

  

	 	(b)	 is permitted to be disclosed pursuant to Clause 8.3 below. 

Permitted Disclosures 
  

	8.3	 The obligations of confidentiality and non-use set forth in Clause 8.1
shall not apply to the extent that the receiving Party or its Affiliates: 

  

	 	(a)	 is required to disclose Confidential Information pursuant to: 

 

	 	(i)	 an order of a court of competent jurisdiction; 

 

	 	(ii)	 Applicable Laws; 

  

	 	(iii)	 regulations or rules of the SEC or other securities exchange; or 

 

	 	(iv)	 the exercise by each Party of its rights granted to it under this Agreement; 

 

	 	(b)	 discloses such Confidential Information solely on a “need to know basis” to Affiliates, potential or
actual acquirers, merger partners, licensees, permitted assignees, collaborators, subcontractors, investment bankers, investors, limited partners, partners, lenders, or other financial partners, and their respective directors, employees, contractors
and agents; 

  

	 	(c)	 provides a copy of this Agreement to the extent requested by an authorized representative of a U.S., U.K.,
Cayman or other foreign tax authority; 

  

	 	(d)	 discloses Confidential Information in response to a routine audit or examination by, or a blanket document
request from, a governmental authority; or 

  

	 	(e)	 in the case of certain Investors, discloses the terms of this Agreement and the Placement Agent Agreement to
prospective investors in, or beneficial owners of, the Investors; 

  
 22 

 provided that, (A) such Third Party or, to the extent applicable, such prospective
investor or beneficial owner (in the case of (e) above) agrees to confidentiality and non-use obligations with respect thereto at least as stringent as those specified for in this Clause 8 (and the
Company agrees that, as to subpart (e) above, the inclusion of a Confidentiality Notice in a Private Placement Memorandum provided to prospective investors in certain of the Investors in connection with this Agreement will satisfy the
requirement set forth in this clause (A)) and (B) to the extent permitted by Applicable Law, the Recipient shall provide prior written notice thereof to the disclosing Party and provide the opportunity for the disclosing Party to review and
comment on such required disclosure and request confidential treatment thereof or a protective order therefor (and the Company agrees that the requirements set forth in this Clause (B) have been satisfied as to the disclosure described in
subpart (e) above). 
 Return of Confidential Information 

 

	8.4	 Each Party shall return or destroy, at the other Party’s instruction, all Confidential Information of the
other Party in its possession upon termination or expiration of this Agreement, or destroy such Confidential Information; provided, however, that each Party shall be entitled to retain one (1) copy of such Confidential Information as may be
required by Applicable Law and neither Party shall be required to return, delete or destroy Confidential Information or any electronic files or any information prepared by such Party that have been backed-up
or archived in the ordinary course of business consistent with past practice. 

  

	9.	 ANNOUNCEMENTS 

 

	9.1	 Except as required by Applicable Law (including disclosure requirements of the SEC, the Nasdaq Global Market or
any other stock exchange on which securities issued by the Company are traded) or for statements that are materially consistent with all or any portion of a previously approved public disclosure, neither Party shall make any other public
announcement or press release concerning this Agreement or the subject matter hereof without the prior written consent of the other, which shall not be unreasonably withheld, conditioned or delayed. In the event of a required public announcement
(other than disclosure about any Party’s financial condition, results of operations, liquidity, capital resources, contractual obligations or commitments, capital requirements or accounting policies, practices, standards or estimates), to the
extent practicable under the circumstances, the Party making such announcement shall provide the other Party (which in the case of the Investors, shall be the Investor Representative) with a copy of the proposed text of such announcement
sufficiently in advance of the scheduled release to afford such other Party a reasonable opportunity to review and comment upon the proposed text provided, however, for clarity, neither Party shall have any obligation to provide the other Party with
a copy of such announcement or accept any comments on the proposed text of such announcement by such other Party. 

  

	9.2	 The Parties shall coordinate in advance with each other if filing of this Agreement (including proposed
redaction of certain provisions of this Agreement) is required under Applicable Law with the SEC or the Nasdaq Global Market or any other stock exchange on which securities issued by a Party or its Affiliate are traded, and each Party shall use
reasonable efforts to seek confidential treatment for the terms of this Agreement proposed to be redacted, if any; provided that each Party shall ultimately retain control over what information to disclose to the SEC, the Nasdaq Global Market or any
other stock exchange or governmental authority, as the case may be. Other than such obligation, neither Party (nor its Affiliates) shall be obligated to consult with or obtain approval from the other Party with respect to any filings to the SEC, the
Nasdaq Global Market or any other stock exchange or governmental authority. 

  

	9.3	 For clarity, once a public announcement or other disclosure is made by a Party in accordance with this Clause 9
then no further consent or compliance with this Clause 9 shall be required for any substantially similar disclosure thereafter. 

  
 23 

	10.	 NOTICES 

  

	10.1	 All notices, requests, demands, approvals, waivers and other communications required or permitted under this
Agreement must be in writing in the English language and shall be deemed to have been received by a Party when: 

  

	 	(a)	 delivered by post on the fifth (5th) Business Day after
posting; 

  

	 	(b)	 delivered by hand, on the day of delivery; and 

 

	 	(c)	 if sent by electronic mail, as soon as the sender receives from the sender’s computer a report of an error
free email transmission to the correct email address. 

  

	10.2	 All such notices and communications shall be addressed as set out below or to such other addresses as may be
given by written notice in accordance with this Clause 10: 

  

			
	If to the Investors:	  	 c/o U.S. Boston Capital Corporation

Attention: John D. McClellan, Jr.
 55 Old Bedford Road, Lincoln,
Massachusetts 01773
 E-mail: jmcclellan@usboston.com

		
	with a copy to:	  	 Attention: Scott E. Pueschel
 Pierce
Atwood LLP
 One New Hampshire Avenue, Suite 350, Portsmouth, New Hampshire 03801

E-mail: spueschel@pierceatwood.com

		
	If to the Company:	  	Attention: Veronique Ameye
		  	E-mail: veronique.ameye@lumiradx.com
		
	with a copy to:	  	 Attention: Ian Lopez
 Fried, Frank,
Harris, Shriver & Jacobson (London) LLP
 100 Bishopsgate, London, EC2N 4AG, United Kingdom

		  	E-mail: ian.lopez@friedfrank.com

  

	11.	 FURTHER ASSURANCES 

The Parties shall (at their own expense) promptly execute and deliver, or cause to be executed or delivered, all such documents and
instruments, and do all such things (which shall include passing any shareholder resolutions that may be required), or cause to do all such things, as any other Party may from time to time reasonably require for the purpose of giving full effect to
and the full benefit of the provisions of this Agreement. 
  

	12.	 COSTS, EXPENSES AND TAXES  

 

	12.1	 The Company agrees to pay the costs and expenses of the Investor Representative reasonably and properly
incurred in connection with (a) the preparation, execution and delivery of this Agreement and the Placement Agent Agreement; and (b) the formation of and sale of interests in (and the preparation, execution and delivery of all documents
necessary thereto) the Investors, including the fees and out-of-pocket expenses of Pierce Atwood LLP, counsel for certain of the Investors, up to $50,000 (the “Expenses”). On or immediately prior to

  
 24 

	 	
the Initial Closing Date, the Investor Representative shall notify the Company in writing of the amount of the Expenses and the Company shall settle such Expenses within ten (10) Business
Days of receipt of such notice. 

  

	12.2	 Subject to Clause 12.1, each Party shall pay its own costs, fees and expenses in connection with the completion
and performance of the transactions contemplated by this Agreement. 

  

	12.3	 All sums payable under this Agreement shall be paid free and clear of all deductions or withholdings, save only
as may be required by law. If, at any time, any applicable law, regulation or regulatory requirement requires any Party to make any deduction or withholding from any sums payable under this Agreement, the amount so due shall be increased to the
extent necessary to ensure that, after the making of such deduction or withholding, the recipient of that payment receives, on the due date for such payment, a net sum equal to the sum which it would have received had no such deduction or
withholding been required to be made. 

  

	12.4	 The Investors and, to the extent applicable, any investor in the Investors shall be responsible for the payment
of any Taxes arising from the sums payable under this Agreement and to make any necessary Tax filings or submissions with respect to any the transactions provided for in this Agreement or the Placement Agent Agreement. 

 

	13.	 ASSIGNMENT 

  

	13.1	 No Party may assign, hold on trust, transfer, charge or otherwise deal with all or any part of its rights or
obligations under this Agreement without the prior written consent of the other Party, provided that this Agreement and the benefits arising under it may be assigned in whole or in the part by the Company to a member of the Company Group (provided
that if such assignee ceases to be a member of the Company Group, this Agreement and the benefits arising under it shall automatically transfer back to the Company immediately prior to such cessation). 

 

	13.2	 Any purported assignment, declaration of trust, transfer,
sub-contracting, delegation, charging or dealing in contravention of Clause 13.1 is ineffective. 

  

	14.	 VARIATION 

This Agreement may only be amended by an instrument in writing duly executed by the Parties. No change, termination, modification or waiver of
any provision of this Agreement shall be binding on the Parties, unless it is made in writing. 
  

	15.	 RIGHTS OF THIRD PARTIES 

Except as expressly stated in this Agreement, this Agreement does not confer any rights on any person or party under the Contracts (Rights of
Third Parties) Act 1999. The Parties may rescind, vary or terminate this Agreement in accordance with its terms without the consent of or notice to any person on whom such rights are conferred. 

 

	16.	 ENTIRE AGREEMENT 

 

	16.1	 This Agreement constitutes the whole agreement between the Parties relating to the transaction to the exclusion
of any terms implied in law that may be excluded by contract. They supersede and extinguish any and all prior discussions, correspondence, negotiations, drafts, arrangements, understandings or agreements relating to the transaction.

  

	16.2	 Each Party agrees and acknowledges that: 

 

	 	(a)	 it is entering into this Agreement in reliance solely on the statements made or incorporated in them;

  
 25 

	 	(b)	 it is not relying on any other statement, representation, warranty, assurance or undertaking made or given by
any person, in writing or otherwise, at any time prior to the date of this Agreement (“Pre-Contractual Statement”); 

 

	 	(c)	 except as expressly provided in this Agreement, it is entering into this Agreement solely in reliance on its
own commercial assessment and investigation and advice from its own professional advisers; and 

  

	 	(d)	 the other Party is entering into this Agreement in reliance on the acknowledgements given in this Clause 16.2.

  

	16.3	 No Party shall have any liability whatsoever for any Pre-Contractual
Statement, whether in contract, in tort, under the Misrepresentation Act 1967 or otherwise. 

  

	16.4	 It is agreed that the only liability of any Party in respect of those statements, representations, warranties,
assurances and undertakings made or given by it and set out or incorporated in this Agreement shall be for breach of contract. 

  

	16.5	 This entire agreement clause does not limit or exclude any liability for fraud. 

 

	17.	 REMEDIES 

The rights and remedies conferred on any Party by, or pursuant to, this Agreement are cumulative, and, except as expressly provided in this
Agreement, are in addition to, and not exclusive of, any other rights and remedies available to such Party at law or in equity. 
  

	18.	 WAIVER 

  

	18.1	 Any waiver of any term or condition of this Agreement, waiver of any breach of any term or condition of this
Agreement, or waiver of, or election whether or not to enforce, any right or remedy arising under this Agreement or at law, must be in writing and signed by or on behalf of the person granting the waiver, and no waiver or election shall be inferred
from a Party’s conduct. 

  

	18.2	 Any waiver of a breach of any term or condition of this Agreement shall not be, or be deemed to be, a waiver of
any subsequent breach. 

  

	18.3	 Failure to enforce any provision of this Agreement at any time or for any period shall not waive that or any
other provision or the right subsequently to enforce all provisions of this Agreement. 

  

	18.4	 Failure to exercise, or delay in exercising, any right or remedy shall not operate as a waiver or be treated as
an election not to exercise such right or remedy, and single or partial exercise or waiver of any right or remedy shall not preclude its further exercise or the exercise of any other right or remedy. 

 

	19.	 SEVERANCE 

If any provision of this Agreement is held to be invalid or unenforceable by any judicial or other competent authority, all other provisions of
this Agreement will remain in full force and effect and will not in any way be impaired. 
  

	20.	 COUNTERPARTS AND DUPLICATES 

This Agreement may be executed in any number of counterparts, but shall not be effective until each Party has signed at least one counterpart.
Each counterpart constitutes an original, and all the counterparts together constitute one and the same agreement. 

  
 26 

	21.	 GOVERNING LAW AND JURISDICTION 

 

	21.1	 This Agreement and any non-contractual obligations arising out of or in
connection with it (including any non-contractual obligations arising out of the negotiation of the transaction contemplated by this Agreement) are governed by and shall be construed in accordance with the
laws of England and Wales. 

  

	21.2	 The Parties irrevocably agree that the courts of England are to have exclusive jurisdiction, and that no other
court is to have jurisdiction to: 

  

	 	(a)	 determine any claim, dispute or difference arising under or in connection with this Agreement, any non-contractual obligations connected with it, or in connection with the negotiation, existence, legal validity, enforceability or termination of this Agreement, whether the alleged liability shall arise under the
law of England and Wales or under the law of some other country and regardless of whether a particular cause of action may successfully be brought in the English courts; and 

 

	 	(b)	 grant interim remedies, or other provisional or protective relief. 

 

	21.3	 The Parties submit to the exclusive jurisdiction of the courts of England and accordingly any proceedings may
be brought against the Parties or any of their respective assets in such courts. 

  

	21.4	 Each of the Parties acknowledges and agrees that damages may not be an adequate remedy for particular breaches
of this Agreement and that each Party shall be entitled (without prejudice to its other rights and remedies) to the equitable remedies of injunction and specific performance 

Service of process 
  

	21.5	 Each of the Investors hereby irrevocably authorises and appoints Scott E. Pueschel of Pierce Atwood LLP, One
New Hampshire Avenue, Suite 350, Portsmouth, New Hampshire 03801 USA to accept on its behalf service of all legal process arising out of or in connection with any proceedings before the courts of England and Wales in connection with this Agreement.

  

	21.6	 The Company hereby irrevocably authorises and appoints LumiraDx UK Ltd, care of 100 More London Riverside, SE1
2AQ, London, UK to accept on its behalf service of all legal process arising out of or in connection with any proceedings before the courts of England and Wales in connection with this Agreement. 

This Agreement is entered into by the Parties on the date written at the beginning of this Agreement. 

  
 27 

 The Parties entered into this Agreement on the day and year first above written. 

 

					
	SIGNED for and on behalf of	 	)	 	/s/ Veronique Ameye
			
	LUMIRADX LIMITED	 	)	 	Signature
			
	by:	 	)	 	Veronique Ameye
			
		 		 	Name
			
	SIGNED for and on behalf of	 	)	 	/s/ John D. McClellan 
			
	USB FOCUS FUND LUMIRADX 2A, LLC	 	)	 	Signature
			
	by:	 	)	 	John D. McClellan
			
		 		 	Name
			
	SIGNED for and on behalf of	 	)	 	/s/ John D. McClellan 
			
	USB FOCUS FUND LUMIRADX 2B, LLC	 	)	 	Signature
			
	by:	 	)	 	John D. McClellan
			
		 		 	Name
			
	SIGNED for and on behalf of	 	)	 	/s/ Leon Okurowski 
			
	PACIFIC PREMIER TRUST CUSTODIAN	 	)	 	Signature
			
	FBO LEON OKUROWSKI ROTH IRA	 	)	 	Leon Okurowski
			
	by:	 		 	Name
			
	SIGNED for and on behalf of	 	)	 	/s/ Willard Umphrey
			
	PACIFIC PREMIER TRUST CUSTODIAN	 	)	 	Signature
			
	FBO WILLARD L. UMPHREY ROTH IRA	 	)	 	Willard Umphrey
			
	by:	 		 	Name
			
	SIGNED for and on behalf of	 	)	 	/s/ John D. McClellan 
			
	PEAR TREE PARTNERS, L.P.	 	)	 	Signature
			
	by:	 	)	 	John D. McClellan
			
		 		 	Name

  
 28

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}]]